Heterocyclic compounds as CDK-HDAC dual pathway inhibitors
By developing novel heterocyclic compounds that simultaneously inhibit CDK and HDAC signaling pathways, the limitations of existing technologies in the treatment efficacy and drug resistance of CDK and HDAC inhibitors used alone have been addressed, enabling effective treatment of various cancers.
Patent Information
- Application Number
- CN201980079367.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-11-30
- Filing Date
- 2019-12-02
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2039-12-02
AI Technical Summary
Existing technologies are unable to effectively inhibit both cyclin-dependent kinases (CDKs) and histone deacetylases (HDACs) simultaneously, resulting in limited cancer treatment efficacy and the tendency for single-target drugs to develop resistance.
A novel heterocyclic compound was developed as a dual-pathway inhibitor that can simultaneously inhibit multiple CDK and HDAC isotypes. By acting on both CDK and HDAC signaling pathways, it enhances anticancer efficacy and reduces drug resistance.
This compound can significantly inhibit the activity of CDK4, CDK6 and HDACs, providing therapeutic advantages for a variety of cancers, including breast cancer, lung cancer, and ovarian cancer, and reducing the risk of drug resistance from monotherapy.
Smart Images

Figure CN113166105B_ABST
Abstract
Description
[0001] Background of the Invention
[0002] Cyclin-dependent kinases (CDKs) are protein kinases involved in important cellular processes, such as cell cycle or transcriptional regulation. There are 13 CDKs kinase subtypes, and different CDK subtypes are responsible for cell cycle activation in quiescent cells and progression of the cell cycle from G1 to mitosis. Each CDK kinase controls a specific checkpoint of the cell cycle. CDK kinases bind to cyclin activation to form a specific complex, thereby being activated. In many human cancers, CDKs are overactive or CDK-inhibited proteins do not function. Therefore, it is reasonable to target CDK function to prevent the uncontrolled spread of cancer cells (Nature Reviews, 2009, 9: 153-166). For example, CDK4 is a key regulator of the G1-S transition. In a complex with cyclin D, CDK4 can phosphorylate Rb and drive cell cycle progression that is inhibited by p16. The p16-CDK4-cyclin D-Rb complex is abnormal in most cancers, so it is an attractive target for cancer therapy.
[0003] Currently, the US FDA has approved two CDK4 / 6 selective inhibitors, Palbociclib (Pfizer) and Ribocilib (Novatis). They are used for the first-line treatment of (HR)+ / HER2- receptor advanced breast cancer. In addition to its strong inhibitory effect on CDK4 and CDK6, Lilly's Abemaciclib also has inhibitory effects on other CDK subtypes (such as CDK2). In September 2017, the FDA approved Abemaciclib for the treatment of certain breast cancers in the United States. Currently, multiple cell cycle regulators have entered clinical research.
[0004] Histone deacetylases (HDACs) are a class of enzymes that remove acetyl groups from the NH2 tails of lysine residues at the ends of core histones. There are currently 18 known human histone deacetylases, which can be divided into four classes based on their attached structures. Class I includes HDAC1, HDAC2, HDAC3, and HDAC8, and has homology to yeast RPD3. HDAC4, HDAC5, HDAC7, and HDAC9 belong to class II, and have homology to yeast HDA1. HDAC6 and HDAC10 contain two catalytic sites and are classified as class IIa, while HDAC11 conserves residues in its catalytic center that are shared by class I and class II acetylases and are sometimes placed in class IV. Histone deacetylase inhibitors (HDACIs) are emerging as a new class of potential anticancer drugs and have been shown to induce differentiation, cell cycle arrest and apoptosis, and inhibit migration, invasion, and angiogenesis in many cancer cell lines. In addition, HDAC inhibitors inhibit tumor growth in animal models and show antitumor activity in patients.
[0005] There is also increasing evidence that HDAC inhibitors have potential for the treatment of non-malignant diseases, such as inflammatory and neurodegenerative diseases.
[0006] Experiments have shown that pan-HDACi can effectively induce G1 growth arrest in a variety of lung cancer cell lines, thereby inhibiting cell proliferation. The inhibitor can effectively reduce the intracellular cyclinD1, CDK2 and CDK4 protein levels, and upregulate the expression levels of P21WAF1 / CIP1 and cyclin E. Experiments have further shown that the inhibitor mainly inhibits HDAC6 activity by downregulating the expression of HDAC6 protein. Pan-HDACi induces HSP90 hyperacetylation in lung cancer cell lines, thereby increasing the degradation of Cyclin D1 and CDK4 in cells.
[0007] Other experiments have shown that Retinoblastoma protein (Rb) forms a nucleosome remodeling complex with HDAC and hSWI / SNF, thereby inhibiting the gene transcription of cyclin E and A and causing the cell cycle to arrest in the G1 phase. Phosphorylation of Rb mediated by cyclinD1 / CDK4 affects its formation of receptors with HDAC, leading to the release of cyclinE gene expression inhibition and G1 phase arrest. Renier Heijkants et al. reported the combined use of CDK inhibitors and HDAC inhibitors to treat subcutaneous uveal metastatic melanoma.
[0008] In summary, small molecule CDK inhibitors (inhibiting one or more isoforms of CDK) can be used to treat a variety of different cancers. In particular, designing a single small molecule to simultaneously inhibit two different targets, CDK and HDAC, is novel and may have an additive effect in treating cancer.
[0009] On the other hand, the literature reports that CDK inhibitors can also be used in combination with other targeted anticancer drugs or antibodies, which have synergistic and synergistic effects on the treatment of cancer. CDK-HDAC dual-pathway inhibitors can also be used in combination with other targeted anticancer drugs or antibodies. Such a combination therapy provides the possibility of acting on multiple targets at the same time, thereby reducing the clinical complexity and technical difficulties of using a single CDK inhibitor + a single HDAC inhibitor + a targeted anticancer drug (or antibody) triple drug combination. The combination of CDK-HDAC dual-pathway inhibitors and other targeted anticancer drugs (or antibodies) can delay the development of drug resistance, increase the anti-tumor effect, and have certain advantages in the treatment of various cancers. In summary, the art needs to provide a new type of CDK-HDAC dual-pathway inhibitor. Summary of the invention
[0010] The present invention provides novel heterocyclic compounds and their uses, for example, as protein kinase inhibitors (such as CDKs) and HDACs. It is particularly noted that the compounds of the present invention have the ability to simultaneously inhibit different subtypes of CDK and different subtypes of HDAC.
[0011] The present invention provides a compound of formula (I), its diastereomers or enantiomers, including deuterated derivatives thereof when possible, and / or its corresponding pharmaceutically acceptable salts, prodrugs, hydrates, and solvates thereof.
[0012] The compounds of formula (I) as shown below, their deuterium derivatives at any available position of the molecule, their diastereomers and enantiomers (where possible):
[0013]
[0014] or its corresponding pharmaceutically acceptable salt, prodrug, hydrate, or solvate, wherein:
[0015] Formula (II):
[0016]
[0017] is a benzene ring, a 5- to 6-membered monocyclic heteroaromatic ring, wherein the monocyclic heteroaromatic ring may optionally contain 1 to 3 heteroatoms independently selected from N, O, and S;
[0018] In formula (II) and formula (I), NH-linked sites on the
[0019] A is a bond, -O-, -C(O)-, -(CR 10 R 11 ) m -、-N(R 12 )-、C 3-8 Cycloalkane structure, 3- to 9-membered heterocyclic ring (optionally containing 1-3 heteroatoms selected from N, O, S), aromatic ring, or heteroaromatic ring; the cycloalkane structure, heterocyclic ring, aromatic ring, heteroaromatic ring may be optionally and independently substituted by 0-4 substituents selected from the following groups: hydroxyl, halogen, C 1-4 Alkyl, C 1-4 Haloalkyl and cyano groups, provided that the chemical structure formed is stable and meaningful. When two hydroxyl groups are simultaneously connected to the same carbon atom in a cycloalkane structure or heterocycle, it means that the two hydroxyl groups and the carbon atom form a carbonyl (i.e. -C(O)-) structure;
[0020] W is a bond, -O-, -C(O)-, -(CR 10 R 11 ) m -、-(CR 10 R 11 ) m NR 12 -、-N(R 12 )-, -OC(O)-, -C(O)O-, -C(O)NH-, -NHC(O)-, -S(O)2-, -S(O)2NH-, -NHS(O)2-, C 3-8 Cycloalkane structure, 3- to 9-membered heterocyclic ring (optionally containing 1-3 heteroatoms selected from N, O, S), aromatic ring, or heteroaromatic ring; provided that A, W, V, R 1 , R 2 , p, and q together form a stable chemical structure; when A and W are both bonds, (CR 1 R 2 ) p -V-(CR 1 R 2 ) q C(O)NH(OH) is directly connected to superior;
[0021] Each R 1 and R 2 are each independently hydrogen, deuterium, halogen, or C 1-4 alkyl;
[0022] or R 1 and R2 The carbon atoms to which it is attached together form a 3- to 9-membered cyclic structure optionally containing 0-3 additional heteroatoms each independently selected from N, O or S; or R 1 and R 2 The carbon atom connected to it together forms a carbonyl group (CR 1 R 2 is C(O));
[0023] R 3 For hydrogen, C 1-8 Alkyl, C 3-8 Cycloalkyl, 3- to 9-membered heterocyclic group (optionally containing 1-3 heteroatoms selected from N, O, S), or C 3-8 Cycloalkylmethyl;
[0024] R 4 For hydrogen, deuterium, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 3-8 Cycloalkyl, or 3- to 9-membered heterocyclic group (optionally containing 1 to 3 heteroatoms selected from N, O, S);
[0025] R 5 and R 6 are independently hydrogen, deuterium, halogen, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 3-8 Cycloalkyl, or 3- to 9-membered heterocyclic group (optionally containing 1-3 heteroatoms selected from N, O, S); wherein R 5 or R 6 At least one of them is fluorine;
[0026] Each R 10 and R 11 are independently hydrogen, deuterium, halogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-8 Cycloalkyl, 3- to 9-membered heterocyclyl (optionally containing 1 to 3 heteroatoms selected from N, O, S), aryl, or heteroaryl;
[0027] or R 10 and R 11 The carbon atoms to which it is attached together form a 3- to 9-membered cyclic structure optionally containing 0-3 additional heteroatoms each independently selected from N, O or S;
[0028] R 12 For hydrogen, C 1-4 Alkyl, R 13 C(O)-、R13 S(O)2-、C 3-8 Cycloalkyl, 3- to 9-membered heterocyclic group (optionally containing 1-3 heteroatoms selected from N, O, S), aryl, or heteroaryl; wherein R 13 For hydrogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-8 Cycloalkyl, 3- to 9-membered heterocyclyl (optionally containing 1 to 3 heteroatoms selected from N, O, S), aryl, or heteroaryl;
[0029] V is a bond, -CR 14 R 15 -, -CH=CH-, -C≡C-, -O-, -S-, -N(R 12 )-, -C(O)-, -OC(O)-, -C(O)O-, -OC(O)O-, -C(O)NH-, -NHC(O)-, -NHC(O)NH-, -S(O)-, -S(O)2-, -S(O)2NH-, -NHS(O)2-, C 3-8 Cycloalkane structure, 3- to 9-membered heterocyclic ring (optionally containing 1-3 heteroatoms selected from N, O, S), aromatic ring, heteroaromatic ring, or -V 1 (CR 1 R 2 ) t V 2 -;
[0030] Among them, R 14 and R 15 are independently hydrogen, deuterium, halogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-8 Cycloalkyl, 3- to 9-membered heterocyclic group (optionally containing 1-3 heteroatoms selected from N, O, S), aryl, heteroaryl, -CN, -OR 16 、-SR 16 、-N(R 17 )2. -C(O)R 13 、-C(O)OR 16 、-C(O)N(R 17 )2. -OC(O)R 13 、-NR 17 C(O)R 13 , or -S(O)2R 13 ; or R 14 and R 15 The carbon atoms connected thereto together form a 3- to 9-membered ring optionally having 0-3 heteroatoms independently selected from N, O or S; wherein R16 For hydrogen, C 1-4 Alkyl, C 3-8 cycloalkyl, 3- to 9-membered heterocyclyl (optionally containing 1-3 heteroatoms selected from N, O, S), aryl, or heteroaryl; each R 17 are independently hydrogen, C 1-4 Alkyl, C 3-8 cycloalkyl, 3- to 9-membered heterocyclyl (optionally containing 1-3 heteroatoms selected from N, O, S), aryl, or heteroaryl; or two R 17 The nitrogen atom to which it is attached together forms a 3- to 9-membered cyclic structure optionally containing 0-3 heteroatoms each independently selected from N, O or S;
[0031] V 1 and V 2 Each independently is a bond, -CR 14 R 15 -, -CH=CH-, -C≡C-, -O-, -S-, -N(R 12 )-, -C(O)NH-, -NHC(O)-, -S(O)2-, -S(O)2NH-, -NHS(O)2-, C 3-8 Cycloalkane structure, 3- to 9-membered heterocyclic ring (optionally containing 1 to 3 heteroatoms selected from N, O, S), aromatic ring, or heteroaromatic ring;
[0032] each p and q are each independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
[0033] m is 0, 1, 2, 3, 4;
[0034] t is 0, 1, 2, 3, 4, 5;
[0035] The prerequisite is V, V 1 、V 2 , p, q and t are able to form a chemically stable structure;
[0036] Each of the above alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkane structure, heterocycle, aromatic ring, and heteroaromatic ring is optionally and independently substituted with 1-3 substituents each independently selected from the group consisting of deuterium, halogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-8 Cycloalkyl, 3- to 9-membered heterocyclic group (optionally containing 1-3 heteroatoms selected from N, O, S), aryl, heteroaryl, -CN, -NO2, -OR 16 、-SR 16 、-N(R 17 )2. -C(O)R13 、-C(O)OR 16 、-C(O)N(R 17 )2、-SO2N(R 17 )2; in the substituent, R 16 For hydrogen, C 1-4 Alkyl, C 3-8 cycloalkyl, 3- to 9-membered heterocyclyl (optionally containing 1-3 heteroatoms selected from N, O, S), aryl, or heteroaryl; each R 17 are independently hydrogen, C 1-4 Alkyl, C 3-8 cycloalkyl, 3- to 9-membered heterocyclyl (optionally containing 1-3 heteroatoms selected from N, O, S), aryl, or heteroaryl; or two R 17 The nitrogen atom connected thereto together forms a 3- to 9-membered cyclic structure optionally containing 0-3 heteroatoms independently selected from N, O or S; the definitions of the remaining groups are as described above;
[0037] Unless otherwise specified, the aryl groups described above contain 6 to 12 carbon atoms; heteroaryl groups are 5- to 15-membered heteroaryl groups.
[0038] In another preferred embodiment,
[0039] A is a bond, -O-, -C(O)-, -(CR 10 R 11 ) m -、-N(R 12 )-, 3- to 9-membered heterocyclic ring (optionally containing 1-3 heteroatoms selected from N, O, S), or heteroaromatic ring; the heterocyclic ring and heteroaromatic ring may be optionally and independently substituted by 0-4 substituents selected from the following groups: hydroxyl, halogen, C 1-4 Alkyl, C 1-4 Haloalkyl and cyano groups, provided that the chemical structure formed is stable and meaningful. When two hydroxyl groups are simultaneously connected to the same carbon atom on a heterocyclic ring, it means that the two hydroxyl groups and the carbon atom form a carbonyl (i.e. -C(O)-) structure;
[0040] W is a bond, -O-, -C(O)-, -(CR 10 R 11 ) m -、-(CR 10 R 11 ) m NR 12 -、-N(R 12)-, -OC(O)-, -C(O)O-, -C(O)NH-, -NHC(O)-, -S(O)2-, -S(O)2NH-, -NHS(O)2-, a 3- to 9-membered heterocyclic ring (optionally containing 1 to 3 heteroatoms selected from N, O, S), or a heteroaromatic ring; provided that A, W, V, R 1 , R 2 , p, and q together form a stable chemical structure; when A and W are both bonds, (CR 1 R 2 ) p -V-(CR 1 R 2 ) q C(O)NH(OH) is directly connected to superior;
[0041] Each R 1 and R 2 are each independently hydrogen, deuterium, halogen, or C 1-4 alkyl;
[0042] or R 1 and R 2 The carbon atoms to which it is attached together form a 3- to 9-membered cyclic structure optionally containing 0-3 additional heteroatoms each independently selected from N, O or S; or R 1 and R 2 The carbon atom connected to it together forms a carbonyl group (CR 1 R 2 is C(O));
[0043] R 3 For hydrogen, C 1-8 Alkyl, C 3-8 Cycloalkyl, or C 3-8 Cycloalkylmethyl;
[0044] R 4 For hydrogen, deuterium, C 1-8 Alkyl, C 3-8 Cycloalkyl;
[0045] R 5 and R 6 are independently hydrogen, deuterium, halogen, C 1-8 Alkyl; wherein R 5 or R 6 At least one of them is fluorine;
[0046] Each R 10 and R 11 are independently hydrogen, deuterium, halogen, C 1-4 alkyl;
[0047] or R10 and R 11 The carbon atoms to which it is attached together form a 3- to 9-membered cyclic structure optionally containing 0-3 additional heteroatoms each independently selected from N, O or S;
[0048] R 12 For hydrogen, C 1-4 Alkyl, R 13 C(O)-、R 13 S(O)2-、C 3-8 Cycloalkyl, 3- to 9-membered heterocyclic group (optionally containing 1-3 heteroatoms selected from N, O, S), aryl, or heteroaryl; wherein R 13 For hydrogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-8 Cycloalkyl, 3- to 9-membered heterocyclyl (optionally containing 1 to 3 heteroatoms selected from N, O, S), aryl, or heteroaryl;
[0049] V is a bond, -CR 14 R 15 -, -CH=CH-, -C≡C-, -O-, -S-, -N(R 12 )-、-C(O)-、C 3-8 Cycloalkane structure, 3- to 9-membered heterocyclic ring (optionally containing 1-3 heteroatoms selected from N, O, S), aromatic ring, heteroaromatic ring, or -V 1 (CR 1 R 2 ) t V 2 -;
[0050] Among them, R 14 and R 15 are independently hydrogen, deuterium, halogen, C 1-4 Alkyl; or R 14 and R 15 The carbon atoms to which they are attached together form a 3- to 9-membered ring optionally having 0-3 heteroatoms each independently selected from N, O or S;
[0051] V 1 and V 2 Each independently is a bond, -CR 14 R 15 -, -CH=CH-, -C≡C-, -O-, -S-, -N(R 12 )-、-C(O)NH-、C 3-8 Cycloalkane structure, 3- to 9-membered heterocyclic ring (optionally containing 1 to 3 heteroatoms selected from N, O, S), aromatic ring, or heteroaromatic ring;
[0052] Each of the above alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkane structure, heterocycle, aromatic ring, and heteroaromatic ring is optionally and independently substituted with 1-3 substituents each independently selected from the group consisting of deuterium, halogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-8 Cycloalkyl, 3- to 9-membered heterocyclic group (optionally containing 1-3 heteroatoms selected from N, O, S), aryl, heteroaryl, -CN, -NO2, -OR 16 、-SR 16 、-N(R 17 )2. -C(O)R 13 、-C(O)OR 16 、-C(O)N(R 17 )2、-SO2N(R 17 )2; where R 13 The definition of R is as above; 16 For hydrogen, C 1-4 Alkyl, C 3-8 cycloalkyl, 3- to 9-membered heterocyclyl (optionally containing 1-3 heteroatoms selected from N, O, S), aryl, or heteroaryl; each R 17 are independently hydrogen, C 1-4 Alkyl, C 3-8 cycloalkyl, 3- to 9-membered heterocyclyl (optionally containing 1-3 heteroatoms selected from N, O, S), aryl, or heteroaryl; or two R 17 The nitrogen atom to which it is attached together forms a 3- to 9-membered ring structure optionally containing 0-3 heteroatoms each independently selected from N, O or S.
[0053] In another preferred embodiment, the definitions of the groups in formula (II) are as follows: R 3 It is for C 1-8 Alkyl, C 3-8 Cycloalkyl, or C 3-8 Cycloalkylmethyl; R 4 For hydrogen, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 3-8 Cycloalkyl, ; R 5 and R 6 are independently hydrogen, halogen, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 3-8 Cycloalkyl; wherein R 5 or R 6 At least one of them is fluorine.
[0054] In another preferred embodiment, R in formula (II) 3 is isopropyl, R 4 is methyl, R 5 is fluorine, R 6 is fluorine; for:
[0055] in express and The NH-linked site on the nucleotide sequence.
[0056] In another preferred embodiment, Selected from the following group: benzene ring, pyridine ring.
[0057] In another preferred embodiment, A is a bond, -O-, -C(O)-, -CH2-, -N(R 12 )-, a 3- to 9-membered heterocyclic ring (optionally containing 1-3 heteroatoms selected from N, O, S), or a heteroaromatic ring; W is a bond, -C(O)-, -CH2-, -N(R 12 )-, -C(O)NH-, -S(O)2-, 3- to 9-membered heterocyclic ring (optionally containing 1 to 3 heteroatoms selected from N, O, S).
[0058] In another preferred embodiment, A and W are both bonds. In this case, (CR 1 R 2 ) p -V-(CR 1 R 2 ) q C(O)NH(OH) is directly connected to superior.
[0059] In another preferred embodiment, each R 1 and R 2 are independently hydrogen or C 1-4 Alkyl; each p and q are each independently 0, 1, 2, 3, 4, 5, or 6.
[0060] In another preferred embodiment, V is selected from the group consisting of a bond, -CH2-, -CH=CH-, -C≡C-, -O-, -S-, -N(R 12 )-、C 3-8 Cycloalkane structure, 3- to 9-membered heterocyclic ring (optionally containing 1-3 heteroatoms selected from N, O, S), aromatic ring, heteroaromatic ring, or -V 1 (CR 1 R 2 ) t V 2 -;
[0061] In another preferred embodiment, V 1 and V 2 Each independently represents a bond, -CH2-, -CH=CH-, -C≡C-, -O-, -S-, -N(R 12 )-、C 3-8 a cycloalkane structure, a 3- to 9-membered heterocyclic ring (optionally containing 1 to 3 heteroatoms selected from N, O, and S), an aromatic ring, or a heteroaromatic ring; and t is 0, 1, 2, or 3.
[0062] In another preferred embodiment, the combination of A and W Select from the following group:
[0063]
[0064] in Indicates that (CR 1 R 2 ) p -V-(CR 1 R 2 ) q The site of C(O)NH(OH) attachment, Representation and The site of attachment. 12 The definition of is as above.
[0065] In another preferred embodiment, A, W and (CR 1 R 2 ) p -V-(CR 1 R 2 ) q The combination of C(O)NH(OH), that is Select from the following group:
[0066]
[0067] in Representation and The site of connection.
[0068] In another preferred embodiment, the compound of formula (I) is:
[0069]
[0070]
[0071] The second aspect of the present invention provides a pharmaceutical composition, which comprises the compound as described in the first aspect of the present invention, and a pharmaceutically acceptable carrier or excipient.
[0072] The third aspect of the present invention provides a use of the compound as described in the first aspect of the present invention in the preparation of a pharmaceutical composition for treating and / or preventing diseases or conditions mediated by cyclin-dependent kinases or histone deacetylases.
[0073] In another preferred embodiment, the disease or condition is selected from the following group: breast cancer, lymphoma, leukemia, lung cancer, ovarian cancer, liver cancer, melanoma, colon cancer, rectal cancer, renal cell carcinoma, small intestine cancer, esophageal cancer, bladder cancer, prostate cancer, or pharyngeal cancer.
[0074] Detailed description of the invention
[0075] definition
[0076] As used herein, use of the terms "a," "an," etc. means one or more unless expressly stated otherwise.
[0077] As used herein, the word "or" has the meaning of "or" and "and", and is equivalent to "and / or" - unless expressly limited to "or" otherwise.
[0078] As used herein, unless otherwise specified, a chiral carbon atom (or chiral center) in a compound of the present invention is optionally in the R form, the S form, or a combination thereof.
[0079] As used herein, unless otherwise indicated, the term "alkyl" by itself or as part of another substituent (which may include the short form of "alkyl", such as alkoxy) refers to a straight chain (i.e., unbranched), branched, or cyclic hydrocarbon group, or combinations thereof, which may be fully saturated, mono- or polyunsaturated and may include divalent and polyvalent groups. When the alkyl group is preceded by a carbon number modification, such as C 1-10 When , it means that the alkyl group contains 1-10 carbon atoms. 1-8 Examples of the alkyl group may include a linear or branched alkyl group having 1 to 8 carbon atoms, such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, and a tert-butyl group.
[0080] As used herein, the term "alkenyl" by itself or as part of another substituent refers to a straight or branched chain hydrocarbon group having at least one carbon-carbon double bond. An alkenyl group having one double bond can be represented as -C n H 2n-1 , with two double bonds represented by -C n H 2n-3 When an olefin group is preceded by a carbon number modification, such as C 2-8 When , it means that the alkenyl group contains 2 to 8 carbon atoms. For example, examples of C2-8 alkenyl groups may include vinyl, allyl, 1,2-butenyl, 2,3-butenyl and butadienyl, etc.
[0081] As used herein, the term "alkynyl" by itself or as part of another substituent refers to an aliphatic hydrocarbon group having at least one carbon-carbon triple bond. The alkynyl group can be straight chain or branched or a combination thereof. In some embodiments, it can contain 2 to 12 (e.g., 2 to 8, 2 to 6, or 2 to 4) carbon atoms. When the alkynyl group is preceded by a carbon atom number modification, such as C 2-8 When , it means that the alkynyl group contains 2-8 carbon atoms. 2-8 Examples of the alkynyl group may include vinyl, propynyl, isopropynyl, 1-butynyl, isobutynyl, sec-butynyl and the like.
[0082] As used herein, the term "cycloalkyl" by itself or as part of another substituent refers to a saturated or partially saturated carbocyclic monocyclic, bicyclic or tricyclic (fused or bridged or spiral) ring system. It may contain 3 to 12 (e.g., 3 to 10, or 5 to 10) carbon atoms. When the cycloalkyl group is preceded by a carbon atom number modification, such as C 3-10 , which means that the cycloalkyl group contains 3 to 10 carbon atoms. In some embodiments, the term "C 3-10 "Cycloalkyl" may refer to a saturated or partially saturated monocyclic or bicyclic alkyl ring system containing 3 to 10 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. The following are some examples of cycloalkyl. A cycloalkane structure is a carbon-hydrogen atom-containing, cyclic, non-aromatic structural fragment derived from a cycloalkyl group, having two attachment sites.
[0083]
[0084] As used herein, the term "alkoxy" or "alkoxy" refers to an alkyl group attached through an oxygen atom (i.e., -O-alkyl), wherein alkyl is as defined above. Specific examples of "alkoxy" include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, cyclohexyloxy, and cyclopentyloxy. The alkoxy group may be optionally substituted with one or more suitable substituents such as halogen, amino, cyano, or hydroxy. The alkoxy group may be straight or branched. When the alkoxy group is preceded by a carbon atom number modification, such as C 1-8 , which means that the alkoxy group contains 1-8 carbon atoms.
[0085] As used herein, the terms "halo" or "halogen" by themselves or as part of another substituent (eg, haloalkyl) may refer to and include F, Cl, Br and / or I.
[0086] As used herein, a "carbonyl" group refers to -C(O)- or -C(=O)-.
[0087] As used herein, the term "aryl" by itself or as part of another substituent refers to and includes monocyclic, bicyclic or polycyclic aromatic groups. Aryl groups may be substituted or unsubstituted. When an aryl group is preceded by a carbon number modification, such as C 6-12 When , it means that the aromatic group contains 6-12 carbon atoms. The aromatic group can be fused to another ring structure containing all carbon (including saturated, partially saturated or aromatic rings). However, the point of attachment to the parent structure must be from the aromatic ring system to be called an aromatic group. When the point of attachment to the parent structure is on a saturated carbon atom, it can be called a cycloalkyl instead of an aryl group. Examples of aromatic groups include, but are not limited to, phenyl, biphenyl and naphthyl. The following are some examples of aromatic groups. An aromatic ring is an aromatic structural fragment containing carbon and hydrogen atoms with two attachment sites derived from the basis of an aromatic group.
[0088]
[0089] As used herein, the term "heteroaryl" by itself or as part of another substituent refers to a monocyclic or polycyclic aromatic hydrocarbon radical having the specified number of ring carbon atoms (e.g., C 4-10 The term "heteroaryl" refers to a 5- to 15-membered aromatic group containing 1 to 4 heteroatoms each independently of N, O or S. The heteroaryl group may include a nitrogen-containing heteroaryl group, an oxygen-containing heteroaryl group, and a sulfur-containing heteroaryl group. The heteroaromatic ring is an aromatic structural fragment derived from a heteroaryl group, having two attachment sites and containing at least one heteroatom selected from N, S, and O in addition to carbon and hydrogen atoms.
[0090] As used herein, the term "nitrogen-containing heteroaryl" refers to an aromatic group having one or more nitrogen atoms in the ring. Preferably, the nitrogen-containing heteroaryl group has 4 to 10 carbon atoms, that is, an aromatic group of 4 to 10 carbon atoms, containing one or more nitrogen atoms in the ring. Specific examples include, but are not limited to, substituted or unsubstituted pyridyl, pyrimidyl and pyrrolyl.
[0091] As used herein, the term "oxygen-containing heteroaryl" refers to an aromatic group having one or more oxygen atoms in the ring. Preferably, it is an aromatic group having 4 to 10 carbon atoms, and an oxygen-containing heteroaryl group having 4 to 10 carbon atoms and having one or more oxygen atoms in the ring, such as furanyl and benzofuranyl which may have a substituent.
[0092] As used herein, the term "sulfur-containing heteroaryl" refers to an aromatic group having one or more sulfur atoms in the ring. Preferably, it is C 4-10 Sulfur-containing heteroaryl, which is an aromatic group having 4 to 10 carbon atoms and one or more sulfur atoms in the ring, for example optionally substituted thienyl.
[0093] Following are some examples of heteroaryl groups.
[0094]
[0095] As used herein, the term "heterocyclyl" by itself or as part of another substituent refers to a monocyclic or polycyclic radical which may be saturated, partially saturated or fully unsaturated, having the specified number of ring carbon atoms (e.g., C 3-11 The term "heterocyclic group" refers to 3 to 11 ring carbon atoms) and contains at least one or more identical or different heteroatoms, each of which is independently N, S or O. A heterocyclic group may be a 3 to 15 membered group containing 1 to 4 heteroatoms, each of which is independently N, O or S. A heterocyclic group may include a nitrogen-containing heterocyclic group, an oxygen-containing heterocyclic group and a sulfur-containing heterocyclic group, a nitrogen-containing and oxygen-containing heterocyclic group, a nitrogen- and sulfur-containing heterocyclic group, a sulfur- and oxygen-containing heterocyclic group, and the like. The following are some examples of heterocyclic groups.
[0096]
[0097] The heterocycle is a cyclic, non-aromatic structural fragment derived from a heterocyclic group, having two connection sites and containing at least one heteroatom selected from N, S, and O in addition to carbon and hydrogen atoms.
[0098] As used herein, the term "optionally" (e.g., as in "optionally substituted with") means that the moiety in question is substituted or unsubstituted, and that substitution occurs only when chemically feasible. For example, H cannot be substituted with a substituent, nor can a covalent bond or a -C(=O)- group be substituted with a substituent.
[0099] As used herein, an "oxo" or "oxide" group refers to =0.
[0100] As used herein, the term "pharmaceutically acceptable salt" - unless otherwise indicated - refers to salts suitable for use in contact with the tissues of a subject (e.g., a human) without undue side effects. In some embodiments, pharmaceutically acceptable salts include salts of compounds of the invention having an acidic group (e.g., potassium salts, sodium salts, magnesium salts, calcium salts) or a basic group (e.g., sulfates, hydrochlorides, phosphates, nitrates, carbonates).
[0101] As used herein, the term "substituted", whether or not preceded by the term "optionally", refers to the replacement of a hydrogen radical in a given structure with a group of a given substituent. Specific substituents are described in the above definitions and in the following descriptions of compounds and examples thereof. Unless otherwise stated, an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted by more than one substituent selected from a particular group, the substituent may be at each identical or different position. Ring substituents such as heterocycloalkyl may be combined with another ring such as cycloalkyl to form a spiro-bicyclic ring system, for example, two rings sharing a common atom. As will be appreciated by one of ordinary skill in the art, the combinations of substituents contemplated by the present invention are those combinations that result in the formation of stable or chemically feasible compounds. Examples of substituents include, but are not limited to, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 3-10 Cycloalkyl, C 1-8 Alkoxy, halogen, hydroxyl, carboxyl (-COOH), C 1-8 Aldehyde, C 2-10 Acyl, C 2-10 For example, phenyl may be optionally substituted with 1 to 3 substituents, each of which is independently halogen, C 1-10 Alkyl, cyano, OH, nitro, C 3-10 Cyclic hydrocarbon, C 1-8 Alkoxy or amino.
[0102] For the sake of convenience and common understanding, the term "optionally substituted" applies only to chemical entities that can be substituted with suitable substituents and does not apply to chemical entities that cannot be chemically substituted.
[0103] Unless specifically defined otherwise, all terms used herein have their ordinary meanings known to those skilled in the art.
[0104] In a preferred embodiment, the compound of formula (I) is selected from the compounds shown above.
[0105] In a preferred embodiment, in formula (I), each of A, W, and V are independently selected from the corresponding groups or structural fragments included in the above-mentioned specific compounds. p and q are independently selected from the parameters that can constitute the above-mentioned specific compounds.
[0106] It should be understood that the compound of formula (I) may also have various derivatives, for example, any hydrogen atom thereof may have a deuterium-enriched derivative, or the compound of formula (I) may form a crystalline form and a salt, etc. The above derivatives can be easily derived by a person skilled in the art after reading the contents disclosed in the present invention.
[0107] General Synthesis Scheme of Compounds of the Invention
[0108] abbreviation
[0109] Boc2O=di-tert-butyl dicarbonate
[0110] Cs2CO3=cesium carbonate
[0111] DCM = dichloromethane
[0112] DIPEA=N,N-diisopropylamine
[0113] DMAP = 4-dimethylaminopyridine
[0114] DMF=N,N-dimethylformamide
[0115] DMSO = dimethyl sulfoxide
[0116] ee = enantiomeric excess
[0117] EtOAc or EA=Ethyl acetate
[0118] HATU = (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate)
[0119] MgCl2=Magnesium chloride
[0120] NH4HCO3=ammonium bicarbonate
[0121] Pd(OAc)2=Palladium(II) acetate
[0122] Pd2dba3=tris(dibenzylideneacetone)palladium(0)
[0123] PE = Petroleum Ether
[0124] RT = Room temperature
[0125] TEA = triethylamine
[0126] TFA = trifluoroacetic acid
[0127] Typically, the reaction is carried out in an inert solvent at a temperature of -40°C to reflux temperature (e.g., 100 or 120°C) for 1 minute to 72 hours, preferably 0.1-24 hours or 0.2-12 hours. Exemplary solvents and temperatures are those used in the Examples.
[0128] Formula (Ia) is a part of formula (I). Scheme A shows the general synthesis of formula (Ia).
[0129] Option A:
[0130]
[0131] The synthesis of intermediate A1 can select a suitable synthesis route according to the specific structure of A1. These synthesis routes are all achievable for organic synthesis personnel in the industry.
[0132] Formula (Ib) is a part of formula (I). Scheme B shows the general synthesis of formula (Ib).
[0133] Plan B
[0134]
[0135] Among them, intermediates B4 and B5 can be synthesized using the following scheme.
[0136]
[0137] Among them, intermediate A3 can be synthesized according to the method reported in the literature: (1) US20100160340; (2) Tetrahedron Letters, 2015, 56(7), 949-951; (3) WO2015130540.
[0138] Compound C12 is part of formula (I). Scheme C shows the general synthesis of compound C12.
[0139] Option C:
[0140]
[0141] Compound D7 is part of formula (I). Scheme D shows the general synthesis of compound D7.
[0142] Plan D:
[0143]
[0144] Compound E9 is part of formula (I). Scheme E shows the general synthesis of compound E9.
[0145] Plan E:
[0146]
[0147] In addition to the schemes of some of the synthetic formulas (I) listed above, there are other schemes of the synthetic formula (I), including exchanging the synthesis order of the schemes listed above, and utilizing different catalysts and synthetic methods. These synthetic schemes and methods are understandable and achievable for organic synthesis technicians and workers, and will not be described one by one here.
[0148] Pharmaceutical compositions and their administration
[0149] The compounds provided by the present invention can be used as kinase inhibitors, in particular as CDK4 and / or CDK6 inhibitors and / or HDAC inhibitors. Therefore, these compounds have excellent therapeutic effects on cancer.
[0150] The pharmaceutical composition of the present invention comprises (i) a safe and effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof and (ii) a pharmaceutically acceptable excipient or carrier. As used herein, the term "safe and effective amount" refers to an amount of a compound sufficient to improve a patient's condition and not cause any serious side effects. Typically, the pharmaceutical composition contains 0.01-100 mg of the compound of the present invention / dose, preferably 0.10-10 mg of the compound of the present invention / dose. In some embodiments, "one dose" refers to a capsule or tablet.
[0151] "Pharmaceutically acceptable carrier" refers to one or more compatible solid or liquid fillers or gel materials suitable for human use, and generally must have sufficient purity and sufficiently low toxicity. The term "compatibility" as used herein means that the components of the composition can be blended with the compounds of the present invention or with each other, and will not significantly reduce the efficacy of the compound. Examples of pharmaceutically acceptable carriers include, but are not limited to, cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid and magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as Tween) agents (such as sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives and pyrogen-free water.
[0152] There is no particular limitation on the route of administration of the compounds or pharmaceutical compositions of the present invention. Representative routes of administration include, but are not limited to, oral, parenteral (intravenous, intramuscular or subcutaneous) and topical administration.
[0153] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier) such as sodium citrate or dicalcium phosphate or with the following components: (a) fillers or compatibilizers, such as starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, such as hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and gum arabic; (c) humectants, such as glycerol; (d) disintegrators such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates and sodium carbonate; (e) dissolution retardants, such as paraffin; (f) absorption promoters, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glyceryl monostearate; (h) adsorbents, such as kaolin; and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also contain buffering agents.
[0154] Solid dosage forms such as tablets, sugar pills, capsules, pills and granules can be prepared by using coatings and shell materials (e.g., enteric coatings and other materials known in the art). They may contain opaque agents, and the release of the active compound or compounds in such compositions may be delayed in certain parts of the digestive tract. Examples of embedded components may be polymers and waxes. If desired, the active compound and one or more of the above excipients may be prepared into microcapsules.
[0155] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may also contain conventional inert diluents known in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, or mixtures thereof, etc.
[0156] Besides inert diluents, the composition may also contain additives such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0157] Suspensions, in addition to the active compounds, may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures thereof and the like.
[0158] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders that can be re-dissolved in sterile injection solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0159] Dosage forms for topical administration of the compounds of this invention include ointments, powders, patches, aerosols and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers or propellants, if desired.
[0160] The compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
[0161] When using a pharmaceutical composition, a safe and effective amount of the compound of the present invention is administered or delivered to a mammal (e.g., a human) in need thereof, wherein the dosage is a pharmaceutically effective amount. For a person weighing about 60 kg, the daily dose is generally 1 to 2000 mg, preferably 20 to 500 mg. Of course, the specific dose should also depend on other factors, such as route of administration, patient health, etc., which are all within the technical scope of a skilled physician.
[0162] The compounds and pharmaceutical compositions of the present invention can be used to treat cancer. As used herein, the term "cancer" is meant to include all types of cancerous growth or carcinogenic processes, metastatic tissues or malignantly transformed cells, tissues or organs, without regard to histopathological type or invasion stage. Examples of cancerous diseases include, but are not limited to, solid tumors, soft tissue tumors and metastatic lesions. Examples of solid tumors include malignant tumors, such as malignant tumors. , such as various organ systems, sarcomas, adenocarcinomas and carcinomas affecting the prostate, lung, breast, lymph, gastrointestinal (e.g., colon) and urogenital tract (e.g., kidney, urothelial cells), pharynx. Adenocarcinomas include malignant tumors, such as most colon cancers, rectal cancers, renal cell carcinomas, liver cancers, non-small cell carcinomas of the lungs, small intestinal cancers and esophageal cancers. Metastatic damage to the above-mentioned cancers can also be treated or prevented using the methods and compositions of the present invention. The methods of the invention can be used to treat malignancies of various organ systems, such as those affecting the lung, breast, lymphoma, gastrointestinal (e.g., colon), bladder, genitourinary tract (e.g., prostate), pharyngeal, and adenocarcinomas, which include malignancies such as most colon, renal cell, prostate, and / or testicular tumors, non-small cell lung cancer, small cell carcinoma, and esophageal cancer. Examples of cancer include, but are not limited to, breast, lymphoma, lung, ovarian, liver, melanoma, colon, rectal, renal cell, small intestine, and esophageal cancers, bladder, prostate, or pharyngeal cancers, and the like.
[0163] The main advantages of the present invention include at least the following:
[0164] (1) The present invention provides novel heterocyclic compounds that can be used as dual-pathway inhibitors of kinases and histone deacetylases. The main feature of the present invention is that a single small molecule can simultaneously inhibit multiple different signaling pathways, such as cell-dependent kinases and histone deacetylases;
[0165] (2) The present invention discloses that these novel heterocyclic compounds of formula (I) have a prominent effect on inhibiting the activities of CDK4, CDK6 and HDACs.
[0166] The present invention will be further described with reference to specific examples. It should be understood that these examples are only used to illustrate the present invention, rather than to limit the scope of the present invention. Unless otherwise specified, parts and percentages are calculated by weight.
[0167] Example 1. Preparation of 7-(4-((6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)pyridin-3-yl)methyl)piperazin-1-yl)-N-hydroxyheptylamide (Compound 1)
[0168]
[0169] Compound 1a (700 mg, 5.07 mmol), N-Boc-piperazine (1.04 g, 5.57 mmol), DIPEA (1.31 g, 10.2 mmol) and HATU (2.889 g, 7.605 mmol) were dissolved in DMF (10 mL). The reaction system was stirred at room temperature overnight, then the reaction solution was poured into water, ethyl acetate was added for extraction (40 mL x 3), the organic phases were combined, saturated brine was added for backwashing, anhydrous magnesium sulfate was added to the organic phase for drying, filtration was performed, and the filtrate was concentrated under reduced pressure at 40°C. The residue was purified by silica gel column chromatography (CH2Cl2 / MeOH=20:1) to obtain white solid 1b (1.0 g, yield: 64%). MS m / z 307.3[M+H] + .
[0170] Compound 1b (400 mg, 1.31 mmol) was dissolved in THF (10 mL), and then a dimethyl sulfide solution of borane (1.0 mol / L, 4.0 mL) was added. The reaction system was stirred at 60°C for 3 hours. Piperidine (1 mL) was then added to the reaction system and stirred at 60°C for 30 minutes. After cooling to room temperature, the reaction system was poured into water and extracted with ethyl acetate (15 mL x 3). The organic phases were combined and washed with saturated brine. Anhydrous magnesium sulfate was added to the organic phase for drying, and the crude product obtained after concentration was separated by silica gel column chromatography (CH2Cl2 / MeOH=20:1) to obtain white solid compound 1c (260 mg, yield: 68%). MS m / z293.0[M+H] + .
[0171] Compound 1c (120 mg, 0.41 mmol), 1d (90 mg, 0.29 mmol, preparation of patent application: US20100160340), Pd (OAc) 2 (9.0 mg, 0.04 mmol), BINAP (25 mg, 0.04 mmol), Cs 2 CO 3 (195 mg, 0.60 mmol) and 1,4-dioxane (5.0 mL) were added to the reaction tube. The reaction system was heated at 120 ° C for 4 hours. The reaction solution was poured into water and extracted with ethyl acetate (10 mL x 3). The combined organic phase was washed once with saturated brine. Anhydrous magnesium sulfate was added to the organic phase for drying, and after filtration, the filtrate was concentrated under reduced pressure at 35 ° C. The obtained residue was purified by preparative thin plate chromatography (CH 2 Cl 2 / MeOH = 20: 1) to obtain a yellow solid 1e (70 mg, yield 43%). MS m / z579.4[M+H] + .
[0172] Compound 1e (70 mg, 0.12 mmol) was dissolved in dichloromethane (5 mL), and trifluoroacetic acid (1.0 mL) was then added. The reaction system was stirred at room temperature overnight. The reaction system was dried under reduced pressure at 40°C to obtain yellow solid compound 1f (85 mg, yield: 100%). MS m / z 479.0 [M+H] + .
[0173] Compound 1g (110 mg, 0.36 mmol) and 1f (85 mg, 0.12 mmol) were dissolved in DMF (3 mL), followed by the addition of K2CO3 (42 mg, 0.30 mmol) and NaI (5 mg, 0.03 mmol), and the reaction system was stirred at 80°C overnight. After cooling to room temperature, the reaction system was added to water and extracted with ethyl acetate (10 mL x 3). After the organic phases were combined, they were washed with saturated brine, and anhydrous magnesium sulfate was added to the organic phase for drying. The crude product obtained after concentration was separated by preparative thin plate chromatography (CH2Cl2 / MeOH=15:1) to obtain yellow solid compound 1h (30 mg, yield: 36%). MS m / z 706.4[M+H] + .
[0174] Compound 1h (30 mg, 0.042 mmol) was dissolved in THF (2 mL), 4M HCl / dioxane (0.5 mL) was slowly added dropwise under ice bath, and stirred at room temperature for 3 hours. The reaction system was dried under reduced pressure at 30°C to obtain a crude yellow solid. Purification by preparative HPLC gave a yellow solid compound, which was the hydrochloride salt of 1 (6.05 mg, yield: 23%). 1 H NMR (400MHz, DMSO-d6): δ10.49 (d, J=14.4Hz, 1H), 10.34 (s, 1H), 8.75 (d, J=3.6Hz, 1H), 8.29 (d, J=3.2Hz, 2H), 8.20 (d, J=8.8Hz, 1H), 7.83-7.81 (m, 1H), 7.72 (d, J=12.0Hz, 1H), 4.90-4.82 (m, 1 H), 5.53-4.12(m, 6H), 3.78(brs, 2H), 3.48(brs, 2H), 3.20-2.85(m, 4H), 2.66(s, 3H), 1.94(t, J =7.2Hz, 2H), 1.64 (s, 3H), 1.63 (s, 3H), 1.62-1.50 (m, 2H), 1.49-1.39 (m, 2H), 1.28-1.20 (m, 4H). MS m / z622.4[M+H] + .
[0175] Example 2. Preparation of 2-((2-((6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)pyridin-3-yl)(methyl)amino)ethyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide (Compound 2)
[0176]
[0177] Compound 2a (0.2 g, 1.41 mmol), 2b (0.27 g, 1.69 mmol) and DIPEA (0.36 g, 2.82 mmol) were added to DMSO (5 mL), and then the reaction system was heated to 100° C. and stirred for 1 hour. After the reaction was completed by TLC monitoring, the reaction solution was cooled to room temperature, poured into an appropriate amount of water, extracted three times with ethyl acetate, the organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate. The crude product obtained after concentration was separated by silica gel column (eluted with a mixed solvent of dichloromethane / methanol=20 / 1) to obtain yellow oily compound 2c (0.3 g, yield: 76%).
[0178] Compound 2c (0.3 g, 1.06 mmol) was added to DMF (10 mL), and then the reaction system was cooled to 0°C, sodium hydride (0.1 g, 2.66 mmol) was slowly added to the reaction system, and iodomethane (0.45 g, 3.19 mmol) was added after the reaction was stirred for 1 hour. After the reaction was completed by TLC monitoring, the reaction solution was cooled to room temperature, poured into an appropriate amount of water, extracted three times with ethyl acetate, the organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate, and concentrated to obtain yellow solid compound 2d (0.28 g, yield: 85%) (the compound can be directly used in the next step without further purification).
[0179] Compound 2d (0.28 g, 0.09 mmol) was added to dichloromethane (5 mL), and a 4M HCl solution in 1,4-dioxane (1 mL) was added dropwise to the solution at 0°C. The reaction solution was stirred at room temperature for 2 hours. After the reaction was completed by TLC, the reaction solution was directly dried to obtain a yellow solid compound 2e (180 mg, yield: 95%). (The compound was not further purified and was directly used in the next step.)
[0180] Compound 2e (280 mg, 1.14 mmol), 2f (254 mg, 1.36 mmol) and DIPEA (293 mg, 2.27 mmol) were added to DMSO (5 mL), and the reaction system was heated to 100 ° C and stirred for 1 hour. After the reaction was completed by LCMS monitoring, the reaction solution was cooled to room temperature, poured into an appropriate amount of water, extracted three times with ethyl acetate, the organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate. The crude product obtained after concentration was slurried with a mixed solvent (dichloromethane / petroleum ether=1 / 5) to obtain a yellow solid compound 2g (250 mg, yield: 61%).
[0181] Compound 2g (250 mg, 2.31 mmol) was dissolved in ethyl acetate / tetrahydrofuran (10 mL, 1 / 1), Pd / C (25 mg) was added thereto, and then the reaction system was replaced with hydrogen three times at room temperature, and stirred at room temperature for 2 hours. After the reaction was completed by TLC monitoring, the reaction system was filtered through diatomaceous earth, and the crude product obtained after the filtrate was concentrated was separated by a silica gel column (washed with a mixed solvent of dichloromethane / methanol = 20 / 1) to obtain an off-white solid compound 2h (180 mg, yield: 78%).
[0182] Compound 2h (180 mg, 0.54 mmol), 2i (211 mg, 0.65 mmol, intermediate 2i is the above intermediate 1d, preparation participates in patent application: US20100160340), Pd2(dba)3 (100 mg, 0.11 mmol), Xantphos (470 mg, 0.82 mmol), Cs2CO3 (532 mg, 1.63 mmol) were dissolved in anhydrous toluene (10 mL), and then the reaction system was replaced with nitrogen three times at room temperature, and then the reaction system was heated to 120 ° C and stirred for 18 hours. The reaction solution was cooled to room temperature, poured into an appropriate amount of water, extracted three times with ethyl acetate, the organic layers were combined and washed with saturated brine, and then dried over anhydrous sodium sulfate. The crude product obtained after concentration was separated by silica gel column (dichloromethane / methanol = 20 / 1 mixed solvent elution) to obtain yellow solid compound 2j (0.18 g, yield: 53%).
[0183] Compound 2j (180 mg, 0.29 mmol) and lithium hydroxide hydrate (122 mg, 2.92 mmol) were dissolved in methanol / water (14 mL / 6 mL), and then the reaction system was heated to 60°C and stirred overnight. After the reaction was completed by TLC monitoring, the methanol was spun off, the pH value of the water layer was adjusted to 5 with 2N hydrochloric acid, and extracted three times with ethyl acetate. The organic layers were combined and concentrated to obtain a light yellow solid compound 2k (140 mg, yield: 82%). (This compound can be directly used in the next step without further purification).
[0184] Compound 2k (140 mg, 0.24 mmol), diisopropylethylamine (62 mg, 0.48 mmol), HATU (136 mg, 0.36 mmol) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (31 mg, 0.26 mmol) were added to dry DMF (15 mL) in sequence. The reaction solution was stirred at 50°C for 2 hours. After the reaction was completed by LCMS detection, the reaction solution was poured into an appropriate amount of water, the generated solid was filtered, and the filter cake was separated and purified by silica gel column chromatography (mixed solvent of dichloromethane / methanol = 25 / 1 to 15 / 1), and the obtained compound 2l was a yellow solid (100 mg, yield: 61%). Compound 2l (25 mg, 0.036 mmol) was added to tetrahydrofuran (1 mL), and a 4M HCl 1,4-dioxane solution (10 drops) was dripped into the solution at room temperature, and then deionized water (10 drops) was added. The reaction solution was stirred at room temperature for 5 hours. After the reaction was completed by LCMS, ether was directly added to the reaction solution until the solid was completely precipitated, and then filtered. The filter cake was washed with ether and acetonitrile and dried to obtain a yellow solid compound, which was the hydrochloride of 2 (15 mg, yield: 68%). MS m / z 604.0 [M+H] + .
[0185] Example 3. Preparation of 7-((6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)pyridin-3-yl)(methyl)amino)-N-hydroxyheptylamide (Compound 3)
[0186]
[0187] Compound hydrogen peroxide (35%, 2.5 mL) was added to concentrated sulfuric acid (6 mL) at 0°C, and then a pre-cooled concentrated sulfuric acid solution of 3a (3a (1.0 g, 8.90 mmol) was dissolved in 6 mL concentrated sulfuric acid) was slowly added to the reaction system and stirred at room temperature for 24 hours. After the reaction was completed by LCMS monitoring, the reaction solution was cooled to room temperature, poured into an appropriate amount of ice, extracted three times with ethyl acetate, the organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate. The crude product obtained after concentration was separated by silica gel column (washed with a mixed solvent of petroleum ether / ethyl acetate = 20 / 1) to obtain a solid yellow solid compound 2a (0.6 g, yield: 47%).
[0188] Compound 2a (100 mg, 0.70 mmol), 3b (165 mg, 0.84 mmol) and DIPEA (182 mg, 1.40 mmol) were added to DMSO (3 mL), and then the reaction system was heated to 100 ° C and stirred for 1.5 hours. After the reaction was completed by LCMS monitoring, the reaction solution was cooled to room temperature, poured into an appropriate amount of water, extracted three times with ethyl acetate, and the organic layers were combined and washed with saturated brine, then dried over anhydrous sodium sulfate, and concentrated to obtain yellow solid compound 3c (0.15 g, yield: 95%). (This compound can be used directly in the next step without further purification).
[0189] Compound 3c (150 mg, 0.53 mmol) was added to DMF (3 mL), and the reaction system was cooled to 0 ° C. Sodium hydride (32 mg, 0.80 mmol) was slowly added to the reaction system, and then the reaction was stirred for 1 hour before adding iodomethane (113 mg, 0.80 mmol). After LCMS monitoring, the reaction solution was cooled to room temperature, poured into an appropriate amount of water, extracted three times with ethyl acetate, the organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate. The crude product obtained after concentration was separated by silica gel column (washed with a mixed solvent of dichloromethane / methanol = 20 / 1), and the solid obtained was slurried with a mixed solvent (dichloromethane / petroleum ether = 1 / 5) to obtain a yellow solid compound 3d (0.14 g, yield: 89%).
[0190] Compound 3d (0.14 g, 0.47 mmol) was dissolved in methanol (5 mL), Pd / C (14 mg) was added thereto, and then the reaction system was replaced with hydrogen three times at room temperature, and stirred at room temperature for 1 hour. After the reaction was completed by TLC monitoring, the reaction system was filtered through diatomaceous earth, and the crude product obtained after the filtrate was concentrated was separated by silica gel column (washed with dichloromethane / methanol = 20 / 1 mixed solvent) to obtain gray solid compound 3e (95 mg, yield 75%).
[0191] Compound 3e (90 mg, 0.34 mmol), 2i (131 mg, 0.41 mmol, Pd2(dba)3 (62 mg, 0.068 mmol), Xantphos (300 mg, 0.51 mmol), Cs2CO3 (332 mg, 1.02 mmol) were dissolved in anhydrous toluene (10 mL), and then the reaction system was replaced with nitrogen three times at room temperature, and then the reaction system was heated to 120°C and stirred for 1 hour. The reaction solution was cooled to room temperature, poured into an appropriate amount of water, extracted three times with ethyl acetate, the organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate. The crude product obtained after concentration was separated by silica gel column (washed with dichloromethane / methanol = 20 / 1 mixed solvent) to obtain yellow solid compound 3f (100 mg, yield: 53%).
[0192] Compound 3f (100 mg, 0.18 mmol) and lithium hydroxide monohydrate (76 mg, 1.81 mmol) were dissolved in tetrahydrofuran / methanol / water (5 mL / 5 mL / 1 mL), and then the reaction system was heated to 60°C and stirred for 18 hours. After the reaction was completed by TLC monitoring, the methanol was removed by spinning, and the pH value of the water layer was adjusted to 5 with 2N hydrochloric acid. The mixture was extracted three times with ethyl acetate, and the organic layers were combined and concentrated to obtain a yellow solid compound 3g (86 mg, yield: 88%). (The compound was not further purified and was directly used in the next step.)
[0193] Compound 3g (86 mg, 0.16 mmol), diisopropylethylamine (62 mg, 0.48 mmol), HOBT (32 mg, 0.24 mmol), EDCI (46 mg, 0.24 mmol), and o-benzylhydroxylamine (24 mg, 0.19 mmol) were added to dry DMF (5 mL) in sequence. The reaction solution was stirred at 50 ° C for 2 hours. After the reaction was completed by thin plate chromatography, the reaction solution was poured into an appropriate amount of water, the generated solid was filtered, and the filter cake was separated and purified by column chromatography (mixed solvent of dichloromethane / methanol = 25 / 1 to 15 / 1) to obtain a yellow solid compound 3h (78 mg, yield: 76%).
[0194] Compound 3h (20 mg, 0.03 mmol) was dissolved in methanol (2 mL), Pd / C (5 mg) was added thereto, and then the reaction system was replaced with hydrogen three times at room temperature, and stirred at 30°C for 18 hours. After the reaction was completed by TLC monitoring, the reaction system was filtered with diatomaceous earth, and ether was added to the filtrate to precipitate solids. The generated solids were filtered, and the filter cake was filtered and washed with acetonitrile / ether (1 / 1) to obtain yellow solid compound 3 (10 mg, yield 58%). MS m / z 553.5[M+H] + .
[0195] Example 4. Preparation of 6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)-N-hydroxynicotinamide (Compound 4)
[0196]
[0197] Compound 4a (100 mg, 0.72 mmol), diisopropylethylamine (280 mg, 2.17 mmol), HATU (413 mg, 1.09 mmol) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (102 mg, 0.87 mmol) were added to dry DMF (15 mL) in sequence. The reaction solution was stirred at room temperature for 2 hours. After the reaction was completed by LCMS detection, the reaction solution was poured into an appropriate amount of water, the generated solid was filtered, and the filter cake was separated and purified by column chromatography (mixed solvent of dichloromethane / methanol = 25 / 1 to 15 / 1), and the obtained compound 4b was a yellow solid (100 mg, yield: 58%).
[0198] Compound 4b (20 mg, 0.084 mmol), 2i (32 mg, 0.10 mmol, Pd2(dba)3 (15 mg, 0.017 mmol), Xantphos (73 mg, 0.13 mmol), Cs2CO3 (82 mg, 0.25 mmol) were dissolved in anhydrous toluene (3 mL), and the reaction system was replaced with nitrogen three times at room temperature, and then the reaction system was heated to 120°C and stirred for 18 hours. The reaction solution was cooled to room temperature, poured into an appropriate amount of water, extracted three times with ethyl acetate, the organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate. The crude product obtained after concentration was separated by silica gel column (eluted with dichloromethane / methanol = 20 / 1 mixed solvent) to obtain yellow solid compound 4c (8 mg, yield: 18%).
[0199] Compound 4c (8 mg, 0.043 mmol) was added to tetrahydrofuran (0.5 mL), 4M HCl in 1,4-dioxane solution (2 drops) was added to the solution at room temperature, and then deionized water (2 drops) was added. The reaction solution was stirred at room temperature for 2 hours. After the reaction was completed by LCMS, ether was directly added to the reaction solution until the solid was completely precipitated, filtered, and the filter cake was washed with ether and acetonitrile and dried to obtain a yellow solid compound, which was the hydrochloride of 4 (2 mg, yield: 18%). MS m / z 440.3 [M+H] + .
[0200] Example 5: Preparation of (E)-3-(6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)pyridin-3-yl)-N-hydroxyacrylamide (Compound 5)
[0201]
[0202] Compound 5a (100 mg, 0.61 mmol), diisopropylethylamine (236 mg, 1.83 mmol), HATU (347 mg, 0.91 mmol) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (86 mg, 0.73 mmol) were added to dry DMF (5 mL) in sequence. The reaction solution was stirred at room temperature for 28 hours. After the reaction was completed by LCMS detection, the reaction solution was poured into an appropriate amount of water, the generated solid was filtered, and the filter cake was separated and purified by column chromatography (mixed solvent of dichloromethane / methanol = 25 / 1 to 15 / 1) to obtain yellow solid compound 5b (80 mg, yield: 50%).
[0203] Compound 5b (20 mg, 0.076 mmol), 2i (29 mg, 0.09 mmol, Pd2(dba)3 (14 mg, 0.015 mmol), Xantphos (66 mg, 0.11 mmol), Cs2CO3 (74 mg, 0.253 mmol) were dissolved in anhydrous toluene (3 mL), and then the reaction system was replaced with nitrogen three times at room temperature, and then the reaction system was heated to 120°C and stirred for 18 hours. The reaction solution was cooled to room temperature, poured into an appropriate amount of water, extracted three times with ethyl acetate, the organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate. The crude product obtained after concentration was separated by silica gel column (eluted with dichloromethane / methanol = 20 / 1 mixed solvent) to obtain yellow solid compound 5c (8 mg, yield: 19%).
[0204] Compound 5c (8 mg, 0.015 mmol) was added to tetrahydrofuran (0.5 mL), 4M HCl in 1,4-dioxane solution (2 drops) was added to the solution at room temperature, and then deionized water (2 drops) was added. The reaction solution was stirred at room temperature for 2 hours. After the reaction was completed by LCMS, ether was directly added to the reaction solution until the solid was completely precipitated, filtered, and the filter cake was washed with ether and acetonitrile and dried to obtain a yellow solid compound, which was the hydrochloride of 5 (2 mg, yield: 27%). MS m / z 466.3 [M+H] + .
[0205] Example 6: Preparation of 4-(((6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)pyridinepyridin-3-yl)(methyl)amino)methyl)-N-hydroxybenzamide (Compound 6)
[0206]
[0207] Compound 6a (5.0 g, 31.54 mmol), N-methylbenzylamine (5.7 g, 47.31 mmol) and DIPEA (8.2 g, 63.08 mmol) were added to DMSO (30 mL), and the reaction system was heated to 100° C. and stirred for 18 hours. After the reaction was completed by LCMS monitoring, the reaction solution was cooled to room temperature, poured into an appropriate amount of water, extracted three times with ethyl acetate, the organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate. The crude product obtained after concentration was separated by silica gel column (eluted with dichloromethane / methanol=20 / 1 mixed solvent) to obtain yellow solid compound 6b (5.0 g, yield: 65%).
[0208] Compound 6b (5.0 g, 20.55 mmol) was added to TFA (20 mL), and then the reaction system was heated to 120° C. and stirred for 48 hours. After the reaction was completed by LCMS monitoring, the reaction solution was cooled to room temperature, poured into a saturated sodium bicarbonate aqueous solution, extracted three times with ethyl acetate, the organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate. The crude product obtained after concentration was separated by silica gel column chromatography (eluted with a mixed solvent of dichloromethane / methanol=10 / 1) to obtain a yellow solid compound 6c (0.5 g, yield: 16%).
[0209] Compound 6c (0.1 g, 0.65 mmol), 6d (0.22 g, 0.98 mmol) and potassium carbonate (0.28 g, 1.96 mmol) were added to acetonitrile (10 mL), and then the reaction system was heated to 80°C and stirred for 18 hours. After the reaction was completed by TLC monitoring, the reaction solution was cooled to room temperature, poured into an appropriate amount of water, extracted three times with ethyl acetate, the organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate. The crude product obtained after concentration was separated by silica gel column chromatography to obtain yellow solid compound 6e (0.12 g, yield: 61%).
[0210] Compound 6e (50 mg, 0.17 mmol), iron powder (46 mg, 0.83 mmol), and ammonium chloride (44 mg, 0.83 mmol) were added to ethanol / water (5 / 1, 10 mL), and the reaction system was heated to 80°C and stirred for 2 hours. After the reaction was completed by thin plate chromatography monitoring, the reaction solution was filtered, the ethanol was spin-dried, an appropriate amount of water was added, and the mixture was extracted three times with ethyl acetate. The organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate. The crude product obtained after concentration was separated by silica gel column chromatography (eluted with a mixed solvent of dichloromethane / methanol = 10 / 1) to obtain a white solid compound 6f (25 mg, yield: 55%).
[0211] Compound 6f (25 mg, 0.092 mmol), 2i (36 mg, 0.11 mmol), Pd2(dba)3 (17 mg, 0.018 mmol), Xantphos (80 mg, 0.14 mmol), Cs2CO3 (90 mg, 0.28 mmol) were dissolved in anhydrous toluene (5 mL), and then the reaction system was replaced with nitrogen three times at room temperature, and then the reaction system was heated to 120°C and stirred for 18 hours. The reaction solution was cooled to room temperature, poured into an appropriate amount of water, extracted three times with ethyl acetate, the organic layers were combined and washed with saturated brine, and then dried over anhydrous sodium sulfate. The crude product obtained after concentration was separated by silica gel column chromatography (dichloromethane / methanol=20 / 1 mixed solvent elution) to obtain yellow solid compound 6g (15 mg, yield: 30%).
[0212] Compound 6g (15 mg, 0.027 mmol) and lithium hydroxide monohydrate (12 mg, 0.27 mmol) were dissolved in methanol / water (5 mL / 1 mL), and then the reaction system was stirred at room temperature for 1 hour. After the reaction was completed by TLC monitoring, the methanol was spun off, the pH value of the water layer was adjusted to 5 with 2N hydrochloric acid, and extracted three times with ethyl acetate. The organic layers were combined and concentrated to obtain yellow solid compound 6h (12 mg, yield: 82%). (This compound can be directly used in the next step without further purification).
[0213] Compound 6h (12 mg, 0.022 mmol), diisopropylethylamine (8 mg, 0.066 mmol), HATU (13 mg, 0.033 mmol) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (3 mg, 0.026 mmol) were added to dry DMF (2 mL) in sequence. The reaction solution was stirred at room temperature for 18 hours. After the reaction was completed by TLC detection, the reaction solution was poured into an appropriate amount of water, the generated solid was filtered, and the filter cake was separated by silica gel column chromatography (eluted with a mixed solvent of dichloromethane / methanol = 25 / 1 to 15 / 1) to obtain a yellow solid compound 6i (8 mg, yield: 56%).
[0214] Compound 6i (8 mg, 0.012 mmol) was added to tetrahydrofuran (1 mL), 4M HCl in 1,4-dioxane solution (1 drop) was added to the solution at room temperature, and then deionized water (1 drop) was added. The reaction solution was stirred at room temperature for 5 hours. After the reaction was completed by LCMS, ether was directly added to the reaction solution until the solid was completely precipitated, filtered, and the filter cake was washed with ether and acetonitrile and dried to obtain a yellow solid compound, which was the hydrochloride of 6 (2 mg, yield: 27%). MS m / z 559.5 [M+H] + .
[0215] Example 7: Preparation of (E)-3-(4-(((6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)pyridin-3-yl)(methyl)amino)methyl)phenyl)-N-hydroxyacrylamide (Compound 7)
[0216]
[0217] Compound 6c (0.1 g, 0.65 mmol), 7a (0.25 g, 0.98 mmol) and potassium carbonate (0.27 g, 1.96 mmol) were added to acetonitrile (10 mL), and the reaction system was heated to 80° C. and stirred for 18 hours. After the reaction was completed by TLC monitoring, the reaction solution was cooled to room temperature, poured into an appropriate amount of water, extracted three times with ethyl acetate, the organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate. The crude product obtained after concentration was separated by silica gel column to obtain yellow solid compound 7b (80 mg, yield: 34%).
[0218] Compound 7b (80 mg, 0.23 mmol), iron powder (65 mg, 1.17 mmol) and ammonium chloride (63 mg, 1.17 mmol) were added to ethanol / water (5 / 1, 10 mL), and then the reaction system was heated to 80°C and stirred for 2 hours. After the reaction was completed by TLC monitoring, the reaction solution was cooled to room temperature, poured into an appropriate amount of water, extracted three times with ethyl acetate, the organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate. The crude product obtained after concentration was separated by silica gel column chromatography (eluted with a mixed solvent of dichloromethane / methanol = 20 / 1) to obtain yellow solid compound 7c (50 mg, yield: 68%).
[0219] Compound 7c (50 mg, 0.16 mmol), 2i (62 mg, 0.62 mmol), Pd2(dba)3 (29 mg, 0.032 mmol), Xantphos (139 mg, 0.24 mmol), Cs2CO3 (160 mg, 0.48 mmol) were dissolved in toluene (5 mL), and then the reaction system was replaced with nitrogen three times at room temperature, and then the reaction system was heated to 120°C and stirred for 1 hour. The reaction solution was cooled to room temperature, poured into an appropriate amount of water, extracted three times with ethyl acetate, the organic layers were combined and washed with saturated brine, and then dried over anhydrous sodium sulfate, and the crude product obtained after concentration was separated by silica gel column chromatography (dichloromethane / methanol=20 / 1 mixed solvent elution) to obtain yellow solid compound 7d (20 mg, yield: 21%).
[0220] Compound 7d (20 mg, 0.034 mmol) and lithium hydroxide hydrate (14 mg, 0.34 mmol) were dissolved in methanol / water (5 mL / 1 mL), and then the reaction system was stirred at room temperature for 1 hour. After the reaction was completed by TLC monitoring, the methanol was spun off, the pH value of the water layer was adjusted to 5 with 2N hydrochloric acid, and extracted three times with ethyl acetate. The organic layers were combined and concentrated to obtain yellow solid compound 7e (15 mg, yield: 75%). (This compound can be directly used in the next step without further purification).
[0221] Compound 7e (15 mg, 0.026 mmol), diisopropylethylamine (9 mg, 0.079 mmol), HATU (15 mg, 0.039 mmol) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (4 mg, 0.040 mmol) were added to dry DMF (2 mL) in sequence. The reaction solution was stirred at 50 ° C for 2 hours. After the reaction was completed by LCMS detection, the reaction solution was poured into an appropriate amount of water, the generated solid was filtered, and the filter cake was separated by silica gel column chromatography (mixed solvent of dichloromethane / methanol = 25 / 1 to 15 / 1) to obtain yellow solid compound 7f (10 mg, yield: 57%).
[0222] Compound 7f (10 mg, 0.015 mmol) was added to tetrahydrofuran (1 mL), 4M HCl in 1,4-dioxane solution (1 drop) was added to the solution at room temperature, and then deionized water (1 drop) was added. The reaction solution was stirred at room temperature for 2 hours. After the reaction was completed by LCMS, ether was directly added to the reaction solution until the solid was completely precipitated, filtered, and the filter cake was washed with ether and acetonitrile and dried to obtain a yellow solid compound, which was the hydrochloride salt of 7 (4 mg, yield: 43%). MS m / z585.5[M+H] + .
[0223] Example 8: Preparation of 4-((4-(6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1 hydrogen-benzoimidazol-6-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperidin-1-yl)methyl)-N-hydroxybenzamide hydrochloride (Compound 8)
[0224]
[0225] Compound 8a (2.0 g, 6.49 mmol) and Pd / C (10%, 200 mg) were added to methanol (20 ml) at room temperature, and the reaction mixture was reacted for 4 hours under a normal pressure atmosphere of hydrogen. TLC monitored the completion of the reaction. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1) to obtain compound 8b (1.62 g, yield 90%).
[0226] Compound 8b (1.0 g, 3.59 mmol) was dissolved in dry toluene (20 mL), and then 1d (1.39 g, 4.31 mmol), cesium carbonate (2.34 g, 7.19 mmol), Pd2(dba)3 (0.66 g, 0.72 mmol) and xantphos (0.72 g, 1.44 mmol) were added in sequence. The reaction system was replaced with nitrogen, and then heated to 120°C in a sealed tube and stirred overnight. After the reaction was completed, the crude product was obtained by filtration and concentration. The crude product was separated by silica gel column chromatography (dichloromethane:
[0227] The mixture was eluted with methanol = 30:1 mixed solvent) to give compound 8c (1.6 g, yield 79%).
[0228] Compound 8c (1.50 g, 2.66 mmol) was dissolved in dichloromethane (10 mL), and a solution of hydrochloric acid in dioxane (4 N, 5 mL) was added under stirring at room temperature. The reaction was stirred at room temperature for 2 hours, and the reaction was completed after monitoring by TLC. The reaction solution was concentrated under reduced pressure to obtain a yellow solid compound 8d (1.33 g, yield 100%).
[0229] Compound 8d (50 mg, 0.10 mmol), 8e (38 mg, 0.12 mmol), and DIPEA (39 mg, 0.30 mmol) were dissolved in DMSO (5 mL). The mixture was heated to 50°C and reacted overnight. The reaction was cooled to room temperature, quenched with water, extracted with ethyl acetate, washed with saturated brine, and dried over anhydrous sodium sulfate to obtain 8f (32 mg, 46%).
[0230] Compound 8f (32 mg, 0.05 mmol) was dissolved in tetrahydrofuran (5 mL), and a solution of hydrochloric acid in dioxane (4N, 2 mL) was added under stirring in an ice bath. The mixture was stirred at room temperature for 4 hours, and the reaction was completed after monitoring by LC-MS. The reaction solution was concentrated under reduced pressure to remove dioxane and tetrahydrofuran, and then acetonitrile was added to precipitate a solid, which was filtered off with suction, and the filter cake was washed with ether to obtain a yellow solid compound 8 (12 mg, yield 40%). 1 H NMR (500MHz, CD3OD) δ8.84 (d, J=3.3Hz, 1H), 8.55 (s, 1H), 8.27 (dd, J=9.7, 2.9Hz , 1H), 8.15 (d, J=11.2Hz, 1H), 7.90 (dd, J=11.6, 5.6Hz, 3H), 7.73 (d, J=8.2Hz, 2H) , 7.57 (d, J=9.6Hz, 1H), 5.12 (m, 1H), 4.53 (s, 2H), 3.93 (s, 2H), 3.61 (d, J=19.3H z, 2H), 3.46-3.37 (m, 2H), 3.33-3.31 (m, 2H), 2.94 (s, 3H), 1.80 (d, J=6.9Hz, 6H). MS m / z 614.6[M+H] + .
[0231] Example 9: Preparation of 7-(4-(6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzoimidazol-6-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperidin-1-yl)-N-hydroxyheptylamide hydrochloride (Compound 9)
[0232]
[0233] The synthesis of compound 9b was the same as that of 8f.
[0234] The synthesis of compound 9 is the same as that of compound 8. 1H NMR (500MHz, DMSO-d6) δ11.56 (s, 1H), 11.21 (s, 1H), 10.33 (d, J=70.7Hz, 1H), 8.85 (s, 1H), 8.30 (s, 1 H), 8.11 (s, 1H), 8.00 (d, J = 2.8Hz, 1H), 7.86 (d, J = 9.5Hz, 1H), 7.79 (d, J = 11.2Hz, 1H), 4.91 (m, 1H), 3 .83 (d, J=12.6Hz, 4H), 3.61 (d, J=12.2Hz, 2H), 3.14 (dt, J=19.6, 5.9Hz, 4H), 2.74 (s, 3H), 1.96 (t, J= 7.3Hz, 2H), 1.75 (s, 2H), 1.64 (d, J=6.9Hz, 6H), 1.52 (dd, J=14.3, 7.1Hz, 2H), 1.30 (d, J=3.0Hz, 4H). MS m / z 608.5[M+H] + .
[0235] Example 10: Preparation of 8-(4-(6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzoimidazol-6-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperidin-1-yl)-N-hydroxy-8-oxooctylamide (Compound 10)
[0236]
[0237] Compound 8d (100 mg, 0.20 mmol), 10a (45 mg, 0.24 mmol), HOBT (41 mg, 0.30 mmol), EDCI (58 mg, 0.30 mmol), DIPEA (52 mg, 0.40 mmol) were dissolved in DMF (5 mL). The reactants were reacted at room temperature overnight. Water was added to extract with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was separated by silica gel column chromatography (eluted with a mixed solvent of dichloromethane: ethyl acetate = 1:1) to obtain compound 10b (86 mg, yield 68%).
[0238] Compound 10b (86 mg, 0.14 mmol) was dissolved in methanol (5 mL), and then an aqueous solution of lithium hydroxide (16 mg, 0.68 mmol) was added dropwise. The reactants were reacted at room temperature overnight. The crude product 10c was directly concentrated to obtain a crude product, which was used directly in the next step without purification.
[0239] Compound 10c (84 mg, 0.14 mmol), O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (19 mg, 0.16 mmol), HOBT (28 mg, 0.20 mmol), EDCI (39 mg, 0.20 mmol), DIPEA (35 mg, 0.28 mmol) were dissolved in DMF (5 mL). The reactants were reacted at room temperature overnight. Water, dichloromethane and methanol (10:1) were added for extraction, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was separated by silica gel column chromatography (dichloromethane: methanol = 50:1 mixed solvent elution) to obtain compound 10d (16 mg, yield 16%).
[0240] The synthesis of compound 10 is the same as that of compound 8. 1 H NMR (500MHz, DMSO-d6) δ11.76 (s, 1H), 10.36 (s, 1H), 8.87 (d, J=3.3Hz, 1H), 8.29 (s, 1H), 8.20 (d, J=9.9Hz, 1H), 7.89 (d, J=2.6Hz, 1H), 7.77 (dd, J=15.7, 10.7Hz, 2H), 4.92 (m, 1H), 3.64 (s, 4H), 3.22 (s, 2H), 3.17 (d, J=1.9Hz, 2H), 2.74 (s, 3H), 2.36 (t, J=7.4Hz, 2H), 1.93 (q, J=7.7Hz, 2H), 1.64 (d, J=6.9Hz, 6H), 1.52-1.45 (m, 4H), 1.27 (dd, J=11.7, 8.7Hz, 4H). MS m / z 636.5[M+H] + .
[0241] Example 11: Preparation of 5-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)-N-hydroxypicolinamide hydrochloride (Compound 11)
[0242]
[0243] Under nitrogen protection, compound 1d (400 mg, 1.24 mmol), 11a (189 mg, 1.24 mmol), cesium carbonate (1.2 g, 3.72 mmol), Pd2(dba)3 (114 mg, 0.12 mmol) and Xantphos (144 mg, 0.25 mmol) were dissolved in 1,4-dioxane (10 mL). The reaction mixture was stirred at 110 ° C for 5 hours. TLC monitored the completion of the reaction. After the reaction solution was cooled to room temperature, methanol (30 mL) was added, stirred and diluted, filtered, and the filter residue was washed with methanol. The obtained off-white solid 11b (468 mg) was directly used in the next step reaction. MS m / z 439.4 [M+H] + .
[0244] Compound 11b (468 mg, 1.07 mmol) was dissolved in a methanol / water mixture (20 mL / 2 mL), and lithium hydroxide monohydrate (137 mg, 3.21 mmol) was added. The reaction mixture was stirred at 60 ° C for 1 hour. TLC monitored the completion of the reaction. The reaction mixture was concentrated under reduced pressure to remove most of the methanol, water (5 mL) was added, the pH was adjusted to 4-5 with hydrochloric acid solution (2N), and extracted with ethyl acetate (3x 10 mL). The combined organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The desiccant was filtered off and the filtrate was concentrated under reduced pressure. The obtained white solid compound 11c (328 mg) was directly used in the next step reaction. MS m / z 425.4[M+H] + .
[0245] Compound 11c (328 mg, 0.77 mmol), O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (108 mg, 0.92 mmol), O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethylurea (441 mg, 1.16 mmol) and diisopropylethylamine (298 mg, 2.31 mmol) were dissolved in N,N-dimethylformamide (5 mL) in sequence. The reaction mixture was stirred at room temperature for 1 hour. TLC monitored the completion of the reaction. The reaction mixture was poured into ice water and extracted with dichloromethane (3x 20 mL). The combined organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The desiccant was filtered off and the filtrate was concentrated under reduced pressure. The crude product was slurried with ethyl acetate (10 mL) to give a white solid compound 11d (325 mg, yield 80%). MS m / z 524.5[M+H] + .
[0246] Compound 11d (325 mg, 0.62 mmol) was dissolved in tetrahydrofuran (5 mL), and then a solution of HCl in 1,4-dioxane (4.0 M, 20 drops) was slowly added. The reaction mixture was stirred at room temperature for 2 hours. TLC monitored the completion of the reaction. The reaction mixture was filtered, and the filter residue was washed with acetonitrile to obtain an off-white solid, which was the hydrochloride salt of compound 11 (195 mg, yield 66%). 1 HNMR (500MHz, DMSO-d6) δ10.46 (s, 1H), 8.95 (d, J = 2.5Hz, 1H), 8.81 (d, J = 3.3Hz, 1H), 8.47 (dd, J = 8.7, 2.6Hz, 1H), 8.36 (s, 1H), 7.97 (d, J=8.7Hz, 1H), 7.89 (d, J=11.5Hz, 1H), 5.05-4.93 (m, 1H), 2.85 (s, 3H), 1.67 (d, J=6.9Hz, 6H). MS m / z 440.6[M+H] + .
[0247] Example 12: Preparation of 2-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)-N-hydroxyisonicotinamide hydrochloride (Compound 12)
[0248]
[0249] Under nitrogen protection, compound 1d (200 mg, 0.62 mmol), 12a (94 mg, 0.62 mmol), cesium carbonate (606 mg, 1.86 mmol), Pd2(dba)3 (57 mg, 0.06 mmol) and Xantphos (72 mg, 0.12 mmol) were dissolved in 1,4-dioxane (5 mL), and the reaction mixture was stirred at 110 ° C for 5 hours. TLC monitored the completion of the reaction. After the reaction solution was cooled to room temperature, the reaction mixture was diluted with methanol (15 mL), filtered, and the filter residue was washed with methanol. The obtained off-white solid 12b (168 mg) was directly used for the next step reaction. MS m / z 439.4 [M+H] + .
[0250] Compound 12b (168 mg, 0.38 mmol) was dissolved in a methanol / water mixture (10 mL / 1 mL), and lithium hydroxide monohydrate (49 mg, 1.14 mmol) was added, and the reaction mixture was stirred at 60 ° C for 1 hour. TLC monitored the completion of the reaction. The reaction mixture was concentrated under reduced pressure to remove most of the methanol, water (5 mL) was added, and the pH was adjusted to 4-5 with hydrochloric acid solution (2N), and extracted with ethyl acetate (3x 10 mL). The combined organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The desiccant was filtered off and the filtrate was concentrated under reduced pressure. The obtained white solid compound 12c (118 mg) was directly used in the next step reaction. MS m / z 425.4[M+H] + .
[0251] Compound 12c (118 mg, 0.28 mmol), O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (40 mg, 0.34 mmol), O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethylurea (160 mg, 0.42 mmol) and diisopropylethylamine (108 mg, 0.84 mmol) were dissolved in N,N-dimethylformamide (3 mL) in sequence, and the reaction mixture was stirred at room temperature for 1 hour. TLC monitored the completion of the reaction. The reaction mixture was poured into ice water and extracted with dichloromethane (3 x 10 mL). The combined organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The desiccant was filtered off and the filtrate was concentrated under reduced pressure. The crude product was then slurried with ethyl acetate (5 mL) to give compound 12d (87 mg, yield 60%) as a white solid. MS m / z 524.5 [M+H] + .
[0252] Compound 12d (87 mg, 0.17 mmol) was dissolved in tetrahydrofuran (2 mL), and then a solution of HCl in 1,4-dioxane (4.0 M, 10 drops) was slowly added. The reaction mixture was stirred at room temperature for 2 hours. TLC monitored the completion of the reaction. The reaction mixture was filtered, and the filter residue was washed with acetonitrile to obtain an off-white solid, which was the hydrochloride salt of compound 12 (49 mg, yield 62%). 1 H NMR (500MHz, DMSO-d6) δ11.58 (s, 1H), 8.90 (d, J = 3.3Hz, 1H), 8.48 (d, J = 5.8Hz, 1H), 8.41 (s, 1H), 8.40 (d, J = 9.0Hz , 1H), 7.95 (d, J=11.4Hz, 1H), 7.50 (dd, J=5.8, 1.6Hz, 1H), 5.04-4.94 (m, 1H), 2.85 (s, 3H), 1.67 (d, J=6.9Hz, 6H). MS m / z 440.4[M+H]+ .
[0253] Example 13: Preparation of 5-(4-(6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperidin-1-yl)-N-hydroxypentanamide hydrochloride (Compound 13)
[0254]
[0255] Compound 13a (160 mg, 0.77 mmol) was dissolved in acetonitrile (5 mL), and methyl 5-bromovalerate (150 mg, 0.77 mmol) and anhydrous potassium carbonate (319 mg, 2.31 mmol) were added. The reaction mixture was stirred at 80 ° C overnight. TLC monitored the completion of the reaction. The reaction mixture was decompressed to remove acetonitrile, and water (10 mL) was added to the obtained solid, which was extracted with ethyl acetate (3 x 20 mL). The combined organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The desiccant was filtered off and the filtrate was concentrated under reduced pressure. The obtained yellow solid compound 13b (238 mg) was directly used in the next step. MS m / z 323.2 [M+H] + .
[0256] Compound 13b (238 mg, 0.74 mmol) and palladium carbon catalyst (10%, 24 mg) were added to methanol (15 mL) at room temperature. The reaction mixture was stirred for 2 hours at room temperature and 1 atmosphere of hydrogen. TLC monitored the completion of the reaction. The reaction mixture was filtered through celite. The filtrate was concentrated under reduced pressure to obtain a brown solid compound 13c (205 mg). The solid was used directly in the next step. MS m / z 293.2 [M+H] + .
[0257] Under nitrogen protection, compound 13c (205 mg, 0.70 mmol), 1d (220 mg, 0.68 mmol), cesium carbonate (663 mg, 2.04 mmol), Pd2(dba)3 (64 mg, 0.07 mmol) and Xantphos (81 mg, 0.14 mmol) were dissolved in 1,4-dioxane (5 mL). The reaction mixture was stirred at 110 ° C for 3 hours. TLC monitored the completion of the reaction. After the reaction solution was cooled to room temperature, the reaction mixture was filtered through diatomaceous earth. The filtrate was then concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 10: 1) to obtain a yellow solid compound 13d (232 mg, yield 59%). MS m / z 579.3 [M+H] + .
[0258] Compound 13d (232 mg, 0.40 mmol) was dissolved in a methanol / water mixture (10 mL / 1 mL), and lithium hydroxide monohydrate (51 mg, 1.20 mmol) was added, and the reaction mixture was stirred at 60 ° C for 3 hours. TLC monitored the completion of the reaction. The reaction mixture was concentrated under reduced pressure to remove most of the methanol, 5 mL of water was added, the pH was adjusted to 4-5 with hydrochloric acid solution (2N), and extracted with ethyl acetate (3x10 mL). The combined organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The desiccant was filtered off and the filtrate was concentrated under reduced pressure. The obtained yellow solid compound 13e (175 mg) was directly used in the next step reaction. MS m / z 565.3[M+H] + .
[0259] Compound 13e (175 mg, 0.31 mmol), O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (43 mg, 0.37 mmol), O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethylurea (211 mg, 0.56 mmol) and diisopropylethylamine (120 mg, 0.93 mmol) were dissolved in N,N-dimethylformamide (3 mL) in sequence, and the reaction mixture was stirred at room temperature for 1 hour. TLC monitored the completion of the reaction. The reaction mixture was poured into ice water and extracted with dichloromethane (3 x 10 mL). The combined organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The desiccant was filtered off and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 20: 1) to obtain yellow solid compound 13f (93 mg, yield 45%). MS m / z 664.3[M+H] + .
[0260] Compound 13f (93 mg, 0.14 mmol) was dissolved in tetrahydrofuran (2 mL), and then a solution of HCl in 1,4-dioxane (4.0 M, 10 drops) was slowly added. The reaction mixture was stirred at room temperature for 2 hours. TLC monitored the completion of the reaction. The reaction mixture was filtered, and the residue was washed with acetonitrile to obtain a yellow solid, which was the hydrochloride salt of compound 13 (59 mg, yield 68%). 1H NMR (500MHz, CD3OD) δ8.87 (d, J=3.2Hz, 1H), 8.59 (s, 1H), 8.29 (dd, J=9.7, 2.6Hz, 1H), 8.19 (d, J=11.0Hz, 1H), 7.95 (d, J=2.7Hz, 1H), 7.59 (d, J=9.6Hz, 1H), 5.20-5.10 (m, 1H ), 3.98-3.90(m, 2H), 3.80-3.71(m, 2H), 3.38-3.31(m, 4H), 3.29-3.23(m, 2H), 2.99(s , 3H), 2.46-2.21(m, 2H), 1.92-1.83(m, 2H), 1.82(d, J=6.9Hz, 6H), 1.77-1.68(m, 2H). MS m / z580.7[M+H] + .
[0261] Example 14: Preparation of 3-(4-(6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperidin-1-yl)-N-hydroxypropanamide hydrochloride (Compound 14)
[0262]
[0263] To a solution of compound 8a (1.5 g, 4.86 mmol) in methanol (40 mL) was slowly added HCl methanol solution (4.0 M, 1.82 mL), and the reaction mixture was stirred at 65 ° C for 2 hours. TLC monitored the completion of the reaction. The reaction mixture was concentrated under reduced pressure. The obtained solid was redissolved in dichloromethane, neutralized with saturated sodium bicarbonate solution, and extracted with dichloromethane (3x 30 mL). The combined organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The desiccant was filtered off and the filtrate was concentrated under reduced pressure. The obtained crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 20: 1, 2% triethylamine) to obtain yellow solid compound 13a (780 mg, yield 77%). MS m / z 209.3 [M + H] + .
[0264] Under nitrogen protection, compound 13a (500 mg, 2.40 mmol), methyl acrylate (310 mg, 3.60 mmol) and triethylamine (730 mg, 7.20 mmol) were added to ethanol, and the reaction mixture was stirred at 50°C overnight. TLC monitored the completion of the reaction. The reaction mixture was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 10: 1) to obtain yellow solid compound 14a (730 mg, yield 100%). MS m / z 295.4 [M+H] + .
[0265] Compound 14a (620 mg, 2.11 mmol) was dissolved in a methanol / water mixture (20 mL / 3 mL), and lithium hydroxide monohydrate (884 mg, 21.07 mmol) was added. The reaction mixture was stirred at 60°C for 1 hour. TLC monitored the completion of the reaction. After the reaction mixture was cooled to room temperature, 4.0 M HCl methanol solution was added thereto to adjust the pH to 3-4. The mixture was concentrated under reduced pressure, and the crude yellow solid compound 14b (591 mg) was directly used in the next step. MS m / z 281.3 [M+H] + .
[0266] Compound 14b (591 mg, 2.11 mmol), O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (297 mg, 2.53 mmol), O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethylurea (1.20 g, 3.16 mmol) and diisopropylethylamine (818 mg, 6.33 mmol) were dissolved in N,N-dimethylformamide (7 mL) in sequence. The reaction mixture was stirred at room temperature for 3 hours. TLC monitored the completion of the reaction. The reaction mixture was concentrated under reduced pressure, and the crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 20: 1) to obtain yellow solid compound 14c (280 mg, two-step yield 35%). MS m / z 380.3 [M+H] + .
[0267] Compound 14c (280 mg, 0.74 mmol) and palladium carbon catalyst (10%, 150 mg) were added to methanol (15 mL) at room temperature, and the reaction mixture was stirred for 2 hours at room temperature and 1 atmosphere of hydrogen. TLC monitored the completion of the reaction. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 10: 1) to obtain a brown solid compound 14d (209 mg, yield 81%). MS m / z 350.5 [M+H] + .
[0268] Under nitrogen protection, compound 14d (209 mg, 0.60 mmol), 1d (212 mg, 0.66 mmol), cesium carbonate (390 mg, 1.20 mmol), Pd2(dba)3 (55 mg, 0.06 mmol) and Xantphos (35 mg, 0.06 mmol) were dissolved in 1,4-dioxane (5 mL), and the reaction mixture was stirred at 110 ° C for 3 hours. TLC monitored the completion of the reaction. After the reaction solution was cooled to room temperature, the reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 10: 1) to obtain a yellow solid compound 14e (134 mg, yield 35%). MS m / z 636.8 [M+H] + .
[0269] Compound 14e (134 mg, 0.21 mmol) was dissolved in dichloromethane (5 mL), and then a solution of HCl in 1,4-dioxane (4.0 M, 40 drops) was slowly added. The reaction mixture was stirred at room temperature for 2 hours. TLC monitored the completion of the reaction. The reaction mixture was filtered, and the filter residue was washed with ether to obtain a yellow solid, which was the hydrochloride salt of compound 14 (95 mg, yield 77%). 1 H NMR (500MHz, CD3OD) δ8.87 (d, J=3.2Hz, 1H), 8.59 (s, 1H), 8.29 (dd, J=9.7, 2.8Hz, 1 H), 8.19 (d, J=11.1Hz, 1H), 7.96 (d, J=2.8Hz, 1H), 7.60 (d, J=9.6Hz, 1H), 5.20-5.11 (m, 1H), 3.98-3.90 (m, 2H), 3.80-3.72 (m, 2H), 3.57 (t, J=7.0Hz, 2H), 3.41-3.31 (m , 4H), 3.03-2.92 (m, 1H), 2.99 (s, 3H), 2.75 (t, J=7.0Hz, 1H), 1.82 (d, J=6.9Hz, 6H). MS m / z 552.6[M+H] + .
[0270] Example 15: Preparation of 1-(6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)pyridin-3-yl)-N-hydroxypiperidine-4-carboxamide hydrochloride (Compound 15)
[0271]
[0272] 2-Nitro-5-bromopyridine 15a (1.5 g, 7.39 mmol), methyl 4-piperidinate (1.27 g, 8.87 mmol), cesium carbonate (4.82 g, 14.78 mmol), Pd2(dba)3 (338 mg, 0.37 mmol) and RuPhos (345 mg, 0.74 mmol) were dissolved in 1,4-dioxane (30 mL), and the reaction mixture was stirred at 110 ° C for 3 hours. TLC monitored the completion of the reaction. After the reaction solution was cooled to room temperature, the reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2: 1) to obtain a yellow solid compound 15b (1.57 g, yield 80%). MS m / z 266.4 [M+H] + .
[0273] Compound 15b (1.0 g, 3.77 mmol) was dissolved in a methanol / water mixture (30 mL / 8 mL), and lithium hydroxide monohydrate (1.58 g, 37.70 mmol) was added. The reaction mixture was stirred at 60°C for 2 hours. TLC monitored the completion of the reaction. After the reaction mixture was cooled to room temperature, 4.0 M HCl methanol solution was added thereto to adjust the pH to 3-4. The mixture was concentrated under reduced pressure, and the crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 20: 1) to obtain yellow solid compound 15c (920 mg, yield 97%). MS m / z 252.3 [M+H] + .
[0274] Compound 15c (400 mg, 1.59 mmol), O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (224 mg, 1.91 mmol), O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethylurea (906 mg, 2.38 mmol) and diisopropylethylamine (617 mg, 4.78 mmol) were dissolved in N,N-dimethylformamide (5 mL) in sequence, and the reaction mixture was stirred at room temperature for 3 hours. TLC monitored the completion of the reaction. The reaction mixture was concentrated under reduced pressure, and the crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 20: 1) to obtain yellow solid compound 15d (676 mg). The solid was directly used in the next step. MS m / z 351.4 [M+H] + .
[0275] Compound 15d (620 mg, 1.77 mmol) and palladium carbon catalyst (10%, 200 mg) were added to methanol (20 mL) at room temperature, and the reaction mixture was stirred for 1 hour at room temperature and 1 atmosphere of hydrogen. TLC monitored the completion of the reaction. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 10: 1) to obtain brown oily compound 15e (363 mg, two-step yield 71%). MS m / z 321.5 [M+H] + .
[0276] Under nitrogen protection, compound 15e (363 mg, 1.13 mmol), 1d (402 mg, 1.25 mmol), cesium carbonate (738 mg, 2.27 mmol), Pd2(dba)3 (103 mg, 0.11 mmol) and Xantphos (65 mg, 0.11 mmol) were dissolved in 1,4-dioxane (6 mL), and the reaction mixture was stirred at 110 ° C for 3 hours. TLC monitored the completion of the reaction. After the reaction solution was cooled to room temperature, the reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 5: 1) to obtain a yellow solid compound 15f (112 mg, yield 16%). MS m / z 607.7 [M+H] + .
[0277] Compound 15f (112 mg, 0.18 mmol) was dissolved in dichloromethane (10 mL), and then a solution of HCl in 1,4-dioxane (4.0 M, 40 drops) was slowly added. The reaction mixture was stirred at room temperature for 2 hours. TLC monitored the completion of the reaction. The reaction mixture was filtered, and the filter residue was washed with ether to obtain a yellow solid, which was the hydrochloride salt of compound 15 (96 mg, yield 93%). 1 H NMR (500MHz, DMSO-d6) δ11.79 (s, 1H), 10.58 (s, 1H), 8.89 (d, J=3.2Hz, 1H), 8.37 (s, 1H), 8.25 (dd, J=9.6, 2.8Hz, 1H), 8.01 (s, 1H), 7.92-7.79 (m, 2H) , 5.01-4.91 (m, 1H), 3.73 (d, J = 12.3Hz, 2H), 3.05-2.85 (d, J = 43.7Hz, 2H), 2.82 (s, 3H), 2.33-2.25 (m, 1H), 1.87-1.71 (m, 4H), 1.66 (d, J=6.9Hz, 6H). MS m / z 523.6[M+H] + .
[0278] Example 16: Preparation of 6′-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)-N-hydroxy-[2,3′-bipyridine]-5-carboxamide hydrochloride (Compound 16)
[0279]
[0280] Under nitrogen protection, methyl 6-chloronicotinate 16a (1.0 g, 5.83 mmol), 6-aminopyridine boronic acid (965 mg, 6.99 mmol), potassium carbonate (1.61 g, 11.66 mmol) and Pd(PPh3)2Cl2 (205 mg, 0.29 mmol) were dissolved in a mixture of tetrahydrofuran / water (16 / 4 mL), and the reaction mixture was stirred at 70°C for 3 hours. TLC monitored the completion of the reaction. After the reaction solution was cooled to room temperature, the reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 15: 1) to obtain a light yellow solid compound 16b (1.2 g, yield 90%). MS m / z 230.4 [M+H] + .
[0281] Under nitrogen protection, compound 16b (400 mg, 1.74 mmol), 1d (619 mg, 1.92 mmol), cesium carbonate (1.14 g, 3.49 mmol), Pd2(dba)3 (159 mg, 0.17 mmol) and Xantphos (101 mg, 0.17 mmol) were dissolved in 1,4-dioxane (15 mL), and the reaction mixture was stirred at 110 ° C for 3 hours. TLC monitored the completion of the reaction. After the reaction solution was cooled to room temperature, the reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 20: 1) to obtain yellow solid compound 16c (324 mg, yield 36%). MS m / z 516.5 [M+H] + .
[0282] Compound 16c (324 mg, 0.63 mmol) was dissolved in a methanol / water mixture (12 mL / 2 mL), and lithium hydroxide monohydrate (264 mg, 6.28 mmol) was added. The reaction mixture was stirred at 60°C for 1 hour. TLC monitored the completion of the reaction. After the reaction mixture was cooled to room temperature, 4.0 M HCl methanol solution was added thereto to adjust the pH to 3-4. The mixture was concentrated under reduced pressure, and the crude yellow solid compound 16d (320 mg) was directly used in the next step. MS m / z 502.5 [M+H] + .
[0283] Compound 16d (320 mg, 0.64 mmol), O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (90 mg, 0.77 mmol), O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethylurea (364 mg, 0.96 mmol) and diisopropylethylamine (247 mg, 1.91 mmol) were dissolved in N,N-dimethylformamide (5 mL) in sequence, and the reaction mixture was stirred at room temperature for 2 hours. TLC monitored the completion of the reaction. The reaction mixture was concentrated under reduced pressure, and the crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 20: 1 to 10: 1) to obtain a light yellow solid compound 16e (330 mg, two-step yield 86%). MS m / z 601.7 [M+H] + .
[0284] Compound 16e (320 mg, 0.53 mmol) was dissolved in dichloromethane (6 mL), and then a solution of HCl in 1,4-dioxane (4.0 M, 5 mL) was slowly added dropwise. The reaction mixture was stirred at room temperature for 1 hour. TLC monitored the completion of the reaction. The reaction mixture was filtered, and the filter residue was washed with ether to obtain a yellow solid, which was the hydrochloride salt of compound 16 (65 mg, yield 22%). 1 H NMR (500MHz, DMSO-d6) δ11.80 (s, 1H), 9.15 (d, J = 2.2Hz, 1H), 9.04 (d, J = 1.8Hz, 1H), 8.93 (d, J = 3.2Hz, 1H), 8.81 (dd, J = 9.1, 2.1Hz, 1H), 8.44 (s , 1H), 8.30 (dd, J=8.3, 2.2Hz, 1H), 8.18 (dd, J=8.7, 2.6Hz, 2H), 7.94 (d, J=11.5Hz, 1H), 5.03-4.94 (m, 1H), 2.85 (s, 3H), 1.69 (d, J=6.9Hz, 6H). MS m / z 517.6[M+H] + .
[0285] Example 17: Preparation of 3-(6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)pyridin-3-yl)-N-hydroxypropynamide hydrochloride (Compound 17)
[0286]
[0287] Under nitrogen protection, compound 17a (500 mg, 2.27 mmol), ethyl propiolate (669 mg, 6.82 mmol), Pd(P(Ph)3)4 (262 mg, 0.45 mmol), CuI (43 mg, 0.23 mmol), DIPEA (2.93 g, 22.7 mmol) were dissolved in DMF (5 mL), and the reaction mixture was stirred at 90 ° C overnight. TLC monitored the completion of the reaction. After the reaction solution was cooled to room temperature, the reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 20: 1) to obtain brown solid compound 17b (128 mg, yield 32%). MS m / z 191.2 [M+H] + .
[0288] Under nitrogen protection, compound 17b (128 mg, 0.73 mmol), 1d (235 mg, 0.73 mmol), cesium carbonate (712 mg, 2.19 mmol), Pd2(dba)3 (64 mg, 0.07 mmol) and Xantphos (81 mg, 0.14 mmol) were dissolved in 1,4-dioxane (5 mL), and the reaction mixture was stirred at 110 ° C for 3 hours. TLC monitored the completion of the reaction. After the reaction solution was cooled to room temperature, the reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 10: 1) to obtain brown solid compound 17c (21 mg, yield 6%). MS m / z 463.2 [M+H] + .
[0289] Compound 17c (21 mg, 0.05 mmol) was dissolved in a methanol / water mixture (10 mL / 1 mL), and lithium hydroxide monohydrate (11 mg, 0.25 mmol) was added, and the reaction mixture was stirred at 60 ° C for 1 hour. TLC monitored the completion of the reaction. The reaction mixture was concentrated under reduced pressure to remove methanol, 5 mL of water was added, and the pH was adjusted to 4-5 with hydrochloric acid solution (2N), and extracted with ethyl acetate (3x10 mL). The combined organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The desiccant was filtered off and the filtrate was concentrated under reduced pressure. The obtained yellow solid compound 17d (17 mg) was directly used in the next step reaction. MS m / z 449.1[M+H] + .
[0290] Compound 17d (17 mg, 0.04 mmol), O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (7 mg, 0.06 mmol), O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethylurea (23 mg, 0.06 mmol) and diisopropylethylamine (15 mg, 0.12 mmol) were dissolved in N,N-dimethylformamide (2 mL) in sequence, and the reaction mixture was stirred at room temperature for 1 hour. TLC monitored the completion of the reaction. The reaction mixture was poured into ice water and extracted with dichloromethane (3x10 mL). The combined organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by preparative thin layer plate (dichloromethane: methanol = 20: 1) to obtain an off-white solid compound 17e (7 mg, yield 34%). MS m / z 548.2 [M+H] + .
[0291] Compound 17e (7 mg, 0.01 mmol) was dissolved in tetrahydrofuran (1 mL), and then a solution of HCl in 1,4-dioxane (4.0 M, 5 drops) was slowly added. The reaction mixture was stirred at room temperature for 2 hours. TLC monitored the completion of the reaction. The reaction mixture was filtered, and the residue was washed with acetonitrile to obtain a brown solid, which was the hydrochloride salt of compound 17 (2 mg, yield 31%). 1 H NMR (500MHz, CD3OD) δ8.86 (d, J=3.2Hz, 1H), 8.63-8.56 (m, 2H), 8.27 (dd, J=9.1, 2.0Hz, 1H), 8.18 (d, J=11.1Hz, 1H), 7.81 (d, J=9.2Hz, 1H), 5.17-5.10 (m, 1H), 2.96 (s, 3H), 1.81 (d, J=6.9Hz, 6H). MS m / z 464.4[M+H] + .
[0292] Example 18: Preparation of 6-((2-((6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)pyridin-3-yl)oxy)ethyl)(methyl)amino)-N-hydroxynicotinamide hydrochloride (Compound 18)
[0293]
[0294] Compound 18a (1.0 g, 6.45 mmol) was dissolved in DMSO (15 mL), and N-methyl-2-hydroxyethylamine (0.60 mL, 7.74 mmol) and anhydrous potassium carbonate (1.78 g, 12.89 mmol) were added. The reaction mixture was stirred at 120 ° C for 18 h. TLC monitored the completion of the reaction. Water (30 mL) was added to the reaction mixture and extracted with ethyl acetate (3x30 mL). The combined organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (dichloromethane: ethyl acetate = 3: 1) to obtain white solid compound 18b (1.0 g, yield 74%). 1 H NMR (500MHz, DMSO-d6) δ8.62 (d, J=2.0Hz, 1H), 7.91 (dd, J=9.1, 2.4Hz, 1H), 6.68 (d, J=9.1H z, 1H), 4.74 (s, 1H), 3.78 (s, 3H), 3.65 (t, J=5.8Hz, 2H), 3.58 (t, J=5.8Hz, 2H), 3.12 (s, 3H).
[0295] Compound 18b (450 mg, 2.14 mmol) was dissolved in DMF (8 mL), and 5-fluoro-2-nitropyridine (334 mg, 2.35 mmol) was added. Sodium hydride (77 mg, 3.21 mmol, 60%) was slowly added under an ice bath. The reaction mixture was stirred at 0°C for 1 h. TLC monitored the completion of the reaction. Water (10 mL) was added to the reaction mixture and filtered to obtain a crude product. The crude product was slurried with ethyl acetate to obtain an off-white solid compound 18c (550 mg, yield 77%).
[0296] Compound 18c (300 mg, 0.90 mmol) and palladium carbon catalyst (10%, 50 mg) were added to methanol (15 mL) at room temperature. The reaction mixture was stirred for 3 hours at room temperature under hydrogen atmosphere. TLC monitored the completion of the reaction. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 50: 1) to obtain a yellow viscous compound 18d (260 mg, 95%).
[0297] Under nitrogen protection, compound 18d (130 mg, 0.43 mmol), 1d (139 mg, 0.43 mmol), cesium carbonate (420 mg, 1.29 mmol), Pd2(dba)3 (12 mg, 0.01 mmol) and Xantphos (15 mg, 0.03 mmol) were dissolved in 1,4-dioxane (6 mL). The reaction mixture was stirred at 100 ° C overnight. TLC monitored the completion of the reaction. After the reaction solution was cooled to room temperature, the reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 100: 1-50: 1) to obtain yellow foam solid compound 18e (180 mg, yield 71%). 1 H NMR (500MHz, CDCl3) δ8.81 (d, J=2.2Hz, 1H), 8.41 (d, J=3.7Hz, 2H), 8.37 (d, J=9.1Hz, 1H), 8 .19 (d, J=1.0Hz, 1H), 8.05 (dd, J=9.0, 2.3Hz, 1H), 8.00 (d, J=2.9Hz, 1H), 7.78 (d, J=11.4Hz, 1H), 7.35 (dd, J=9.2, 2.8Hz, 1H), 6.54 (d, J=9.0Hz, 1H), 4.78-4.68 (m, 1H), 4.26 (t, J=5.5H z, 2H), 4.10 (t, J=5.4Hz, 2H), 3.87 (s, 3H), 3.25 (s, 3H), 2.70 (s, 3H), 1.70 (d, J=7.0Hz, 6H). MS m / z 589.6[M+H] + .
[0298] Compound 18e (175 mg, 0.30 mmol) was dissolved in a mixture of tetrahydrofuran / water / methanol (10 mL / 2 mL / 2 mL), and sodium hydroxide (60 mg, 1.49 mmol) was added. The reaction mixture was stirred at 60 ° C for 4 hours. TLC monitored the completion of the reaction. The reaction mixture was concentrated under reduced pressure to remove most of the organic solvent, and the pH was adjusted to 5-6 with hydrochloric acid solution (2N), and extracted with a mixture of dichloromethane and methanol (v / v=10 / 1) (3x20 mL). The combined organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The desiccant was filtered off and the filtrate was concentrated under reduced pressure. The obtained yellow solid compound 18f (130 mg) was directly used in the next step reaction. MS m / z 575.5[M+H] + .
[0299] Compound 18f (130 mg, 0.23 mmol), O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (32 mg, 0.27 mmol), O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethylurea (129 mg, 0.34 mmol) and diisopropylethylamine (59 mg, 0.45 mmol) were dissolved in N,N-dimethylformamide (5 mL) in sequence, and the reaction mixture was stirred at 50°C overnight. TLC monitored the completion of the reaction. The reaction mixture was poured into ice water and extracted with a mixture of dichloromethane and methanol (v / v=10 / 1) (3x20 mL). The combined organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 50: 1), and then separated by preparative thin plate chromatography to obtain 18 g (100 mg, yield 66%) of a yellow solid compound. 1 H NMR (500MHz, CDCl3) δ9.02 (s, 1H), 8.61 (d, J = 2.1Hz, 1H), 8.52 (s, 1H), 8.41 (d, J = 3.7Hz, 1H), 8.36 (d, J = 9.1Hz, 1H), 8.17 (d, J=1.1Hz, 1H), 8.11 (s, 1H), 7.91 (dd, J=9.0, 2.3Hz, 1H), 7.77 (d, J=11.6Hz, 1H), 7.32 (dd, J=9.1, 2.9Hz, 1H), 6.54 (d, J=9.0Hz, 1H), 5.08 (s, 1H), 4.73 (m, 1H), 4.23 (t, J=5.6Hz, 2H), 4.08-4. 00 (m, 3H), 3.65 (m, 1H), 3.21 (s, 3H), 2.69 (s, 3H), 1.87 (m, 3H), 1.69 (d, J=7.0Hz, 6H), 1.66-1.54 (m, 3H). MS m / z 674.7[M+H] + .
[0300] Compound 18g (100 mg, 0.15 mmol) was dissolved in tetrahydrofuran (5 mL), and then a solution of HCl in 1,4-dioxane (4.0 M, 10 drops) was slowly added. The reaction mixture was stirred at room temperature for 2 hours. TLC monitored the completion of the reaction. The reaction mixture was filtered, and the filter residue was washed with acetonitrile to obtain a yellow solid, which was the hydrochloride salt of compound 18 (90 mg, yield 88%). 1H NMR (500MHz, CD3OD) δ8.87 (d, J=3.2Hz, 1H), 8.58 (d, J=0.8Hz, 1H), 8.38 (s, 1H), 8.32 (d, J=9.7Hz, 1H), 8.19 (d, J=11.3Hz, 1H), 8.12-8.06 (m, 2H), 7.58 ( d, J=9.4Hz, 1H), 7.54 (d, J=9.2Hz, 1H), 5.21-5.13 (m, 1H), 4.50 (t, J=4.9Hz, 2H), 4.25 (t, J=4.8Hz, 2H), 3.46 (s, 3H), 2.98 (s, 3H), 1.81 (d, J=6.9Hz, 6H). MS m / z 590.7[M+H] + .
[0301] Example 19: Preparation of 2-((2-((6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)pyridin-3-yl)oxy)ethyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide hydrochloride (Compound 19)
[0302]
[0303] Compound 19a (1.0 g, 5.88 mmol), (2-methoxyethyl)methylamine (662 mg, 8.82 mmol) and potassium carbonate (1.62 g, 11.75 mmol) were dissolved in DMSO (10 mL). The reaction mixture was stirred at 120 ° C for 18 h. TCL detected that the reaction was complete. Water (30 mL) was added to the reaction mixture and extracted with ethyl acetate (3x30 mL). The combined organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography to obtain white solid compound 19b (1.0 g, yield 76%).
[0304] Compound 19b (1.0 g, 4.44 mmol) and 2-fluoro-5-nitropyridine (757 mg, 5.33 mmol) were dissolved in DMF (10 mL). Sodium hydride (266 mg, 6.66 mmol, 60%) was slowly added under an ice bath and stirred for 20 min, then the mixture was stirred at room temperature until the reaction was complete. Water (10 mL) was added to the reaction mixture and filtered to obtain a light yellow solid. The solid was slurried with ethyl acetate to obtain an off-white solid compound 19c (0.9 g, yield 58%). MS m / z 293.2 [M+H] + .
[0305] Compound 19c (300 mg, 0.86 mmol) and palladium carbon catalyst (10%, 50 mg) were added to methanol (15 mL) at room temperature. The reaction mixture was stirred for 1 hour at room temperature and 1 atmosphere of hydrogen. TLC monitored the completion of the reaction. The reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain a crude white solid compound 19d (260 mg, yield 96%). The solid was used directly in the next step. MS m / z 318.3 [M+H] + .
[0306] Under nitrogen protection, compound 19d (200 mg, 0.63 mmol), compound 1d (244 mg, 0.76 mmol), cesium carbonate (410 mg, 1.26 mmol), Pd2(dba)3 (57 mg, 0.06 mmol) and Xantphos (73 mg, 0.12 mmol) were dissolved in 1,4-dioxane (5 mL). The reaction mixture was stirred at 110 ° C for 18 hours. TLC monitored the completion of the reaction. After the reaction solution was cooled to room temperature, the reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 10: 1) to obtain yellow solid compound 19e (180 mg, yield 47%). MS m / z 604.7 [M+H] + .
[0307] Compound 19e (232 mg, 0.29 mmol) was dissolved in a mixture of tetrahydrofuran / water / methanol (10 mL / 2 mL / 2 mL), and sodium hydroxide (60 mg, 1.49 mmol) was added. The reaction mixture was stirred at 70 ° C for 4 hours. TLC monitored the completion of the reaction. The reaction mixture was concentrated under reduced pressure to remove most of the organic solvent, and the pH was adjusted to 5-6 with hydrochloric acid solution (2N), and extracted with a mixture of dichloromethane and methanol (v / v=10 / 1) (3x20 mL). The combined organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The desiccant was filtered off and the filtrate was concentrated under reduced pressure. The crude yellow solid compound 19f (150 mg, yield 87%) was directly used in the next step. MS m / z 576.5[M+H] + .
[0308] Compound 19f (150 mg, 0.26 mmol), O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (34 mg, 0.29 mmol), O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethylurea (180 mg, 0.29 mmol) and diisopropylethylamine (100 mg, 0.78 mmol) were dissolved in N,N-dimethylformamide (5 mL) in sequence, and the reaction mixture was stirred at 50°C for 1 hour. TLC monitored the completion of the reaction. The reaction mixture was poured into ice water and extracted with dichloromethane (3x10 mL). The combined organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (dichloromethane: methanol = 20: 1) to obtain yellow solid compound 19g (100 mg, yield 57%). 1 H NMR (500MHz, CDCl3) δ9.26 (s, 1H), 8.73 (s, 3H), 8.42 (d, J = 3.7Hz, 1H), 8.36 (d, J = 9.1Hz, 1H) , 8.17 (d, J = 1.1Hz, 1H), 8.09 (d, J = 2.9Hz, 1H), 7.78 (d, J = 11.6Hz, 1H), 7.33 (dd, J = 9.2, 3.0Hz , 1H), 5.08 (s, 1H), 4.73-4.70 (m, 1H), 4.21 (t, J=5.5Hz, 2H), 4.06-4.01 (m, 3H), 3.66-3.64 (m , 1H), 3.35 (s, 3H), 2.69 (s, 3H), 1.88-1.83 (m, 3H), 1.68 (d, J=5.0Hz, 1H), 1.66-1.58 (m, 3H).
[0309] Compound 19g (70 mg, 0.10 mmol) was dissolved in tetrahydrofuran (2 mL), and then a solution of HCl in 1,4-dioxane (4.0 M, 10 drops) was slowly added. The reaction mixture was stirred at room temperature for 2 hours. TLC monitored the completion of the reaction. The reaction mixture was filtered, and the filter residue was washed with acetonitrile to obtain a yellow solid, which was compound 19 hydrochloride (60 mg, yield 92%). 1H NMR (500MHz, CD3OD) δ8.86 (d, J=3.2Hz, 1H), 8.78 (s, 2H), 8.58 (d, J=0.9Hz, 1H), 8.19 (d, J=11.0Hz, 1H), 8.11 (dd, J=9.6, 2.9Hz, 1H), 8.06 (d, J=2. 8Hz, 1H), 7.57 (d, J=9.6Hz, 1H), 5.20-5.11 (m, 1H), 4.45 (t, J=5.4Hz, 2H) , 4.23 (t, J=5.4Hz, 2H), 3.40 (s, 3H), 2.98 (s, 3H), 7.57 (d, J=10.0Hz, 1H). MS m / z 591.7[M+H] + .
[0310] Example 20: Biological testing.
[0311] 1.CDK2, CDK4 and CDK6 kinase assays:
[0312] The in vitro enzymatic activities of various CDK isoforms CDK2 / CycA2, CDK4 / CycD3 and CDK6 / cycD3 were measured using a mobility shift assay to monitor the phosphorylation ratio of FAM-labeled peptides (peptide 18 for CDK2 / CycA2 and peptide 8 for CDK4 / CycD3). The activities of CDK2 / CycA2 and CDK6 / cycD3 were tested under the following buffer conditions: 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.0015% Brij-35 and 2 mM dithiothreitol; the activities of CDK4 / CycD3 were tested under the following buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 0.01% Triton X-100 and 2 mM dithiothreitol. Compounds were prepared at 50 times the final desired maximum inhibitor concentration using 100% DMSO and a total of 10 concentrations were prepared using a 3-fold serial dilution method. For each kinase isoform, the enzyme and substrate doses were: CDK2 / CycA2 12nM, ATP Km 39μM; CDK4 / CycD3 10nM, ATP Km 221μM; CDK6 / cycD3 15nM, ATP Km 800μM. The assays were performed at 28°C for 60 min, 180 min, and 60 min, respectively, and the reactions were terminated with stop solution (50mM EDTA, 0.015% Brij-35, 0.2% coating reagent #3, and 100mM HEPES (pH 7.5)). Conversion rates were collected on a Caliper EZ Reader. IC was calculated by fitting dose-response curves using Xlfit excel add-in version 4.3.1 50 Numeric value.
[0313] The test results of representative compounds are listed in Table 1 below. The inhibitory activity at the enzyme level is represented by the letters A, B, C, D, and E. Among them, A represents IC 50 Less than 10nM, B represents IC 50 Greater than or equal to 10nM, but less than 100nM, C stands for IC 50 Greater than or equal to 100nM, but less than 500nM, D represents IC 50 Greater than or equal to 500nM, but less than 1000nM, E stands for IC 50 Greater than or equal to 1000nM.
[0314] Compound <![CDATA[CDK4(IC 50 ,nM)]]> <![CDATA[CDK6(IC 50 ,nM)]]> <![CDATA[CDK2(IC 50 ,nM)]]> 1 A B B 2 A B C 3 A B B 4 A C C 5 A C B 6 A B A 7 B D C 8 A B B 9 A B B 10 A A B 11 A B A 12 B E B 13 A A B 14 A B B 15 A B B 16 A B A 17 A
[0315] 2. HDAC-1, HDAC-2 and HDAC-6 activity test:
[0316] The inhibitory effect of the compound on HDAC-1, HDAC-2 and HDAC-6 function was determined in vitro using an optimized homogenous assay performed in a 384-well plate format. In this test, recombinant, full-length HDAC-1, HDAC-2 or HDAC-6 protein (BPS Biosciences) was cultured with Ac-peptide-AMC at a concentration in the Km map. The reaction was carried out in a Tris-based assay buffer, and 7-amino-4-methylcoumarin was then released from the substrate fluorescence under the enzymatic activity of deacetylases and trypsin. Fluorescence measurements were obtained using a multi-label plate reader (Synergy MX, 355nm excitation and 460nm emission). The data were analyzed on a plate-by-plate basis to establish the linear range of fluorescence over time. The data were fitted to GraphPad Prism V5.0 software using the formula (Y = bottom + (top - bottom) / (1 + 10^((LogIC 50 -X)*slope) to get IC 50 value, Y is % inhibition, X is compound concentration).
[0317] The test results of representative compounds are listed in Table 1 below. The inhibitory activity at the enzyme level is represented by the letters A, B, C, D, and E. Among them, A represents IC 50 Less than 10nM, B represents IC 50 Greater than or equal to 10nM, but less than 100nM, C stands for IC 50 Greater than or equal to 100nM, but less than 500nM, D represents IC 50 Greater than or equal to 500nM, but less than 1000nM, E stands for IC 50 Greater than or equal to 1000nM.
[0318] Table 2 HDAC-1 and HDAC-6 biological tests
[0319]
[0320]
[0321] Other embodiments of the present invention
[0322] The present invention has been described above with reference to specific examples and embodiments, but is not constructed in any way to limit the scope of the present invention. It should be understood that various modifications and additions can be made to the disclosed specific examples and embodiments without departing from the spirit of the present invention, and such modifications and additions are considered to be part of the present invention.
Claims
1. A compound represented by the following formula (I), or its diastereomer or enantiomer: or a corresponding pharmaceutically acceptable salt thereof, wherein: Formula (II): is a 6-membered monocyclic heteroaromatic ring, wherein the monocyclic heteroaromatic ring contains 1 N atom; In formula (II) and formula (I), NH-linked sites on the R 3 For hydrogen, C 1-8 Alkyl, C 3-8 Cycloalkyl, or C 3-8 Cycloalkylmethyl; R 4 For hydrogen, deuterium, C 1-8 Alkyl, C 3-8 Cycloalkyl; R 5 and R 6 each independently is fluorine; A, W and (CR 1 R 2 ) p -V-(CR 1 R 2 ) q The combination of C(O)NH(OH), that is Select from the following group: in Representation and The site of connection.
2. A compound selected from the group consisting of:
3. A pharmaceutical composition, characterized in that The invention comprises a compound as claimed in any one of claims 1 to 2, and a pharmaceutically acceptable carrier or excipient.
4. The use of a compound as described in any one of claims 1 to 2 in the preparation of a pharmaceutical composition for treating and / or preventing a disease or condition mediated by a cyclin-dependent kinase or a histone deacetylase; the disease or condition being selected from the group consisting of breast cancer, lymphoma, leukemia, lung cancer, ovarian cancer, liver cancer, melanoma, colon cancer, rectal cancer, renal cell carcinoma, small intestine cancer, esophageal cancer, bladder cancer, prostate cancer, or pharyngeal cancer.
